



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁶ : A23K 1/165 | A1 | (11) International Publication Number: WO 95/16360 (43) International Publication Date: 22 June 1995 (22.06.95) |
| (21) International Application Number: PCT/EP94/04212 (22) International Filing Date: 19 December 1994 (19.12.94) (30) Priority Data: 08/169,948 17 December 1993 (17.12.93) US (71) Applicants (for all designated States except US): FINNFEEDS INTERNATIONAL LIMITED [GB/GB]; Market House, Ailesbury Court, High Street, Marlborough, Wiltshire SN8 1AA (GB). GENENCOR INTERNATIONAL INC. [US/US]; 4 Cambridge Place, 1870 Winton Road South, Rochester, NY 14618 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BEDFORD, Michael, Richard [GB/GB]; Finnfeeds International Limited, Market House, Ailesbury Court, High Street, Marlborough, Wiltshire SN8 1AA (GB). MORGAN, Andrew, John [GB/GB]; Finnfeeds International Limited, Market House, Ailesbury Court, High Street, Marlborough, Wiltshire SN8 1AA (GB). FOWLER, Timothy [US/US]; Nr. 304, 1000 Continental Way, Belmont, CA 94002 (US). CLARKSON, Kathleen, A. [US/US]; 53 28th Street, San Francisco, CA 94110 (US). WARD, Michael [US/US]; 4372 24th Street, San Francisco, CA 94114 (US). COLLIER, Katherine, D. [US/US]; 658 | | Oakpark Way, Redwood City, CA 94062 (US). LARENAS, Edmund [US/US]; 352 Caprino Way, San Carlos, CA 94070 (US). (74) Agents: HANSEN, Bernd et al.; Hoffmann, Eitle & Partner, Arabellastrasse 4, D-81925 München (DE). (81) Designated States: AU, CA, CN, CZ, FI, HU, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: AN ENZYME FEED ADDITIVE AND ANIMAL FEED INCLUDING IT (57) Abstract <p>The use is provided of a composition as a feed additive which comprises one or more endoglucanases, and 0-20 % by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase. The endoglycanases may be one or more of EGI, EGII, EGIII and any functionally active derivative of any thereof. Such endoglucanases may be obtained from a genetically modified strain of the fungus <i>Trichoderma</i>. Also provided is an enzyme-based feed additive which comprises EGI and/or EGII which lack the cellulose binding domain, and 0-20 % by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. A further enzyme-based feed additive is provided which comprises a cereal-based carrier, one or more endoglucanases, and 0-20 % by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. Such enzyme-based feed additives can be incorporated into a cereal-based feed which includes one or more of barley, wheat, triticale, rye and maize. The feed additive has the advantage of improving the feed conversion ratio and/or increasing the digestibility of a cereal-based feed in which it is included.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

AN ENZYME FEED ADDITIVE AND ANIMAL FEED INCLUDING IT

The present invention relates to an enzyme feed additive, and in particular to such an additive which can decrease the feed conversion ratio of a cereal-based feed and/or increase its digestibility.

Improvements in animal feeds to enable animals to digest them more efficiently are constantly being sought. One of the main concerns is to improve the feed conversion ratio (FCR) of a feed without increasing its cost per unit weight. The FCR is the ratio of the amount of feed consumed relative to the weight gain of an animal. A low FCR indicates that a given amount of feed results in a growing animal gaining proportionately more weight. This means that the animal is able to utilise the feed more efficiently. One way in which the FCR of a feed can be improved is to increase its digestibility.

There are various constraints on the digestibility of the nutritional components of a feed such as its starch, fat, protein and amino acid content. These constraints include:

- (i) the viscosity of materials present in the animal's gut. Such viscosity is due, at least in part, to soluble non-starch polysaccharides such as mixed-linked β -glucans and arabinoxylans;
- (ii) entrapment of nutrients within the cell walls of the feed, particularly those of the aleurone

layer in cereals. Such entrapment is caused by the high levels of non-starch polysaccharides in the cell walls of cereals which are relatively resistant to break-down by the animal's digestive system. This prevents the nutrients entrapped within the cells from being nutritionally available to the animal; and

- (iii) a deficiency in endogenous enzyme activity, both of the animal and of the gut microbial population particularly in a young animal.

The above problems which interfere with digestibility are particularly noticeable in the case of cereal-based diets, and in particular those having a high barley content.

Due to the problem of poor digestibility of nutrients from the feed, it is normally necessary to formulate feeds to contain higher levels of energy providing materials in order to meet the nutritional demands of animals. Such energy providing materials conventionally include starch, fat, sugars, fibre etc. The requirement of including these energy providing materials, or sources of such materials, in a feed adds a considerable extra cost which is disadvantageous from an economic view point.

In an attempt to solve the problem of poor digestibility of cereal-based feeds, it is known to include enzyme supplements such as β -glucanases or xylanases in animal feeds. For example, WO 91/04673 discloses a feed

additive for alleviating malabsorption syndrome in poultry which causes reduced digestion. The additive includes a cellulase and a xylanase. JP-A-60-75238 discloses a feed for domestic animals which contains an enzyme cocktail including protease-, cellulase-, amylase- and lipase-activities. This reference speculates that these various enzyme activities enable fermentation microbes to grow and that these become useful nutritional components of the feed.

Whole cellulase is a mixture of different enzymes which cooperate to hydrolyze cellulose (β -1,4-D-glucan linkages) and/or derivatives thereof (e.g. phosphoric acid swollen cellulose) and give as primary products compounds such as glucose, cellobiose, and cellooligosaccharides. Whole cellulase is made up of several different enzyme classifications including enzymes having exo-cellobiohydrolase activity, endoglucanase activity and β -glucosidase activity.

For example, the whole cellulase produced by the fungus *Trichoderma longibrachiatum* comprises two exo-cellobiohydrolases, CBHI and CBHII, at least three endoglucanases, EGI, EGII and EGIII, and at least one β -glucosidase. A representative fermentation from *T.longibrachiatum* may produce a whole cellulase including by protein weight 45-55% CBHI, 13-15% CBHII, 11-13% EGI, 8-10% EGII, 1-4% EGIII and 0.5-1% BG. However, it should be noted that actual concentrations of a specific cellulase component will vary according to numerous factors, including fermentation conditions, substrate concentrations and strain type. Thus, in a

- 4 -

representative fermentation, *Trichoderma longibrachiatum* produces a whole cellulase having from 58-70% of cellobiohydrolases.

Each endoglucanase of *T. longibrachiatum* has its own distinct characteristics. Thus, EGI in addition to cellulase activity is known to hydrolyze xylan. EGII and EGIII by comparison do not show significant xylanase activity, at least according to azo-xylan native PAGE overlay. Further, it is known that EGI, EGII and EGV contain structurally distinct cellulose binding domains (CBD's). On the other hand, EGIII does not appear to contain a structurally distinct binding domain and has been shown to have a lower affinity for crystalline cellulose compared to EGI or EGII.

WO 92/06209 discloses processes for transforming the filamentous fungus *Trichoderma reesei* (now called "*T. longibrachiatum*") which involves the steps of treating a *T. reesei* strain with substantially homologous linear recombinant DNA to permit homologous transformation and then selecting the resulting *T. reesei* transformants. For instance, transformants are described in which certain targeted genes are deleted or disrupted within the genome and extra copies of certain native genes such as those encoding EGI and EGII are homologously recombined into the strain. It is noted in this reference that cellulase compositions obtained from strains deficient in CBHI and CBHII components are useful as components of a detergent cleaning composition. Such cellulase compositions are of course relatively enriched

- 5 -

When used *in vivo*, endoglucanases and cellobiohydrolases are considered to act synergistically in the hydrolysis of cellulose to small cello-oligosaccharides (mainly cellobiose), which are subsequently hydrolysed to glucose by the action of β -glucosidase. In addition to hydrolyzing the β -1,4 linkages in cellulose, endo-1,4- β -glucanase (EC 3.2.1.4) will also hydrolyze 1,4 linkages in β -glucans also containing 1,3-linkages. The endoglucanases act on internal linkages to produce cellobiose, glucose and cello-oligosaccharides. The cellobiohydrolases act on the chain ends of cellulose polymers to produce cellobiose as the principal product.

Whole cellulase obtained from *T. longibrachiatum* has been used in combination with barley in fields such as brewing and in animal nutrition for several years. One of the benefits of adding cellulases to barley-based diets for livestock is to increase the digestibility of various components present in the diet including protein and amino acids. As a result, dietary input costs can be reduced without loss of performance, and excretion of nitrogen in the manure can be significantly reduced. This reduces the environmental impact of intensive livestock farming.

Endosperm cell walls of barley contain a high proportion of high molecular weight, water-soluble mixed-linked β -(1,3)(1,4)-glucans. When solubilised, these polysaccharides cause an increase in the solution's viscosity. For example, if barley is fed to broiler chickens, this leads to a relatively high level of

- 6 -

viscosity in the region of their gastrointestinal tract, which results in reduced efficiency of digestion and growth depression.

Organisms which produce or express cellulase enzyme complexes often also express xylanase activity. For example, two different xylanase enzymes produced by *T. longibrachiatum* have been identified. The purification of these two different xylanases, one referred to as high pI xylanase (having a pI of about 9.0) and the other referred to as low pI xylanase (having a pI of about 5.2), as well as the cloning and sequencing of the gene for each xylanase is described in detail in WO 92/06209 and WO 93/24621. Figure 16 of this document sets out the deduced amino acid sequences for both the low pI and high pI gene products. Example 22 also teaches how to create *T. longibrachiatum* strains which over-express the low pI and high pI xylanase genes.

As mentioned above, the use of cellulases as an additive to animal feeds is known in the art. Such cellulases of course possess a natural balance between their cellobiohydrolase and endoglucanase contents. As also mentioned above, in naturally occurring strains of *T. longibrachiatum*, the CBHs may comprise 58-70% by weight of the cellulase proteins.

The present invention is based upon a study to identify which components of the cellulase proteins are able to improve the nutritional benefits of cereal-based feeds such as those including barley. Specific attention has been paid to the effects of the individual enzymes

- 7 -

constituting whole cellulase, and in particular the endoglucanases, on viscosity reduction of soluble mixed-linked β -(1,3)(1,4)-glucans of barley. This is because this is known to be one of the primary modes of action of whole cellulase. The present invention has been made as a result of this research to identify those specific components of the cellulase enzyme system, and their relative amounts, which advantageously improve the feed conversion ratio (FCR) of a cereal-based feed and/or increase its digestibility.

In the description and claims which follow, the following are definitions of some of the technical terms which are employed.

"Fungal cellulase" means an enzyme composition derived from fungal sources or microorganisms genetically modified so as to incorporate and express all or part of the cellulase genes obtained from a fungal source.

The term "*Trichoderma*" refers to any fungal strain which is or has previously been classified as *Trichoderma* or which is currently classified as *Trichoderma*. Such species include *Trichoderma longibrachiatum*, *Trichoderma reesei* and *Trichoderma viride*.

The term "EG" refers to any endoglucanase, for example EGI, EGII, EGIII or EGV produced by *T. longibrachiatum*, or any derivative of any such endoglucanase which possesses endoglucanase activity.

- 8 -

An EG "derivative" includes for example, EGI, EGII, EGIII and EGV from *Trichoderma* in which there is an addition of one or more amino acids to either or both of the C- and N- terminal ends of the EG, a substitution of one or more amino acids at one or more sites throughout the EG, a deletion of one or more amino acids within or at either or both ends of the EG, or an insertion of one or more amino acids at one or more sites in the EG such that endoglucanase activity is retained in the derivatized EG. The term EG "derivative" also includes the core domains of the endoglucanase enzymes that have attached thereto one or more amino acids from the linker regions.

The term "truncated cellulase", as used herein, refers to a protein comprising a truncated cellulase core of exo-cellobiohydrolase or endoglucanase, for example, EGI, EGII, EGV, CBHI and CBHII, or derivatives of either. EGV is described in *Molecular Microbiology*, Vol. 13, No. 2 (1994) at pages 219-228. As stated above, many cellulase enzymes, such as EGI, EGII and EGV, are believed to be bifunctional in that they contain regions or domains which are directed toward both catalytic or hydrolytic activity with respect to the cellulose substrate, and also non-catalytic cellulose binding activity. Thus, a truncated cellulase is a cellulase which lacks binding domain cellulose binding activity.

It is believed that the catalytic core and the cellulose binding domain of a cellulose enzyme act together in a synergistic manner to effect efficient hydrolysis of cellulose fibers in a cellulose containing feed. It is

- 9 -

further believed that cellulase catalytic activity and cellulose binding activity may be identified as being specific to distinct structural regions, or may be present in the same structural region. For example, as indicated above, many cellulase enzymes, including several of those from *T. longibrachiatum* are known to incorporate a catalytic core domain subunit which is attached via a linker region to a cellulose binding domain subunit. However, other cellulase enzymes are believed to have a catalytic core domain which is structurally integral to a cellulose binding domain, e.g., the two regions are not separated by a linker and do not represent distinct structural entities. In such a cellulase enzyme, it is believed that a specific peptide or group of related amino acid residues may be responsible for cellulose binding activity. Accordingly, it is within the scope of the present invention that such a binding domain would be altered so as to reduce the cellulose binding activity of the cellulase by, for example, genetic engineering or chemical modification.

A "truncated cellulase derivative" encompasses a truncated cellulase core, as defined herein, wherein there may be an addition or deletion of one or more amino acids to either or both of the C- and N- terminal ends of the truncated cellulase, or a substitution, insertion or deletion of one or more amino acids at one or more sites throughout the truncated cellulase. Derivatives are interpreted to include mutants that preserve their character as truncated cellulase core, as defined below. It is also intended that the term "derivative of a truncated cellulase" includes core domains of the

- 10 -

exoglucanase or endoglucanase enzymes that have attached thereto one or more amino acids from the linker regions.

A truncated cellulase derivative further refers to a protein substantially similar in structure and biological activity to a truncated cellulase core domain protein, but which has been genetically engineered to contain a modified amino acid sequence. Thus, provided that the two proteins possess a similar activity, they are considered "derivatives" as that term is used herein even if the primary structure of one protein does not possess the identical amino acid sequence to that found in the other.

It is contemplated that a truncated cellulase derivative may be derived from a DNA fragment encoding a truncated catalytic core domain which further contains an addition of one or more nucleotides internally or at the 5' or 3' end of the DNA fragment, a deletion of one or more nucleotides internally or at the 5' or 3' end of the DNA fragment or a substitution of one or more nucleotides internally or at the 5' or 3' end of the DNA fragment wherein the functional activity of the catalytic core domain (truncated cellulase derivative) is retained. Such a DNA fragment ("variant DNA fragment") comprising a cellulase catalytic core may further include a linker or hinge DNA sequence or portion thereof which is attached to the core or binding domain DNA sequence at either the 5' or 3' end wherein the functional activity of the encoded truncated cellulase core domain (truncated cellulase derivative) is retained.

The term "truncated cellulase core" or "truncated cellulase region" refers herein to a peptide comprising

the catalytic core domain or region of exo-cellobiohydrolase or endoglucanase, for example, EGI, EGII or EGIII or a derivative thereof that is capable of enzymatically cleaving cellulose polymers, including but not limited to pulp or phosphoric acid swollen cellulose. However, a truncated cellulase core will not possess cellulose binding activity attributable to a cellulose binding domain or region. A truncated cellulase core is distinguished from a non-truncated cellulase which, in an intact form, possesses no cellulose binding domain or region. A truncated cellulase core may include other entities which do not include cellulose binding activity attributable to cellulose binding domain or region. For example, the presence of a linker or hinge is specifically contemplated. Similarly the covalent attachment of another enzymatic entity to the truncated cellulase core is also specifically contemplated.

The performance (or activity) of a protein containing a truncated catalytic core or a derivative thereof may be determined by methods well known in the art. (See Wood, T.M. et al. in Methods in Enzymology, Vol. 160, Editors: Wood, W.A. and Kellogg, S.T., Academic Press, pp. 87-116, 1988). For example, such activities can be determined by hydrolysis of phosphoric acid-swollen cellulose and/or soluble oligosaccharides followed by quantification of the reducing sugars released. In this case the soluble sugar products, released by the action of cellobiohydrolase or endoglucanase cellulase core domains or derivatives thereof, can be detected by HPLC analysis or by use of colorimetric assays for measuring reducing sugars. It is expected that these catalytic domains or

derivatives thereof will retain at least 10% of the activity exhibited by the intact enzyme when each is assayed under similar conditions and dosed based on similar amounts of catalytic domain protein.

The term "cellulose binding domain" refers herein to an amino acid sequence of the endoglucanase comprising the binding domain of an endoglucanase, for example, EGI or EGII, that non-covalently binds to a polysaccharide such as cellulose. It is believed that cellulose binding domains (CBDs) function independently from the catalytic core of the endoglucanase enzyme to attach the protein to cellulose. Truncated endoglucanases used in this invention lack the CBD but include at least the core or catalytic domain.

The term "linker region" or "hinge region" refers to the short peptide region that links together the two distinct functional domains of the fungal endoglucanases, i.e., the core domain and the binding domain. These domains in *T. longibrachiatum* cellulases are linked by a peptide rich in Ser, Thr and Pro.

A "signal sequence" refers to any sequence of amino acids bound to the N-terminal portion of a protein which facilitates the secretion of the mature form of the protein outside of the cell. This definition of a signal sequence is a functional one. The mature form of the extracellular protein lacks the signal sequence which is cleaved off during the secretion process.

The term "host cell" means both the cells and protoplasts created from the cells of *Trichoderma*.

The term "DNA construct or vector" (used interchangeably herein) refers to a vector which comprises one or more DNA fragments or DNA variant fragments encoding any one of the truncated endoglucanases or derivatives described above.

The term "functionally attached to" means that a regulatory region, such as a promoter, terminator, secretion signal or enhancer region is attached to a structural gene and controls the expression of that gene.

The term "whole cellulase" means the complete cellulase system as produced by a naturally occurring microorganism.

Based upon the above considerations, it is an object of the present invention to provide enzyme-based feed additives which improve the FCR and/or increase the digestibility of a cereal-based feed.

According to one aspect, the present invention provides the use of a composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase.

As mentioned above, whole cellulase from *T. longibrachiatum* (i.e. strains occurring naturally) typically contains 58-70% by weight of cellobiohydrolases

or more based on the total weight of enzymes having cellulase activity. The composition for use as a feed additive provided by the present invention may be obtained by enriching the content of endoglucanases produced by a suitable microorganism through purification, addition of purified endoglucanase or by adding additional genes to overproduce endoglucanase. In addition, or alternatively, the relative content of cellobiohydrolases produced by the microorganism may be decreased compared to whole cellulase through purification procedures or by modifying or deleting those genes which encode cellobiohydrolase. It is particularly preferred that the feed additive should be free of cellobiohydrolases, so that their content in the additive is 0% by weight.

In a second aspect, the present invention provides an enzyme-based feed additive which comprises at least one of EGI^{III}, EGI which lacks the cellulose binding domain and EGII which lacks the cellulose binding domain, and 0-20% by weight based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.

The production of such structurally modified endoglucanases by genetic engineering techniques is described in detail below.

In a third aspect, the present invention provides an enzyme-based feed additive comprising a cereal-based carrier, one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. In such an additive,

- 15 -

the cereal-based carrier may be milled wheat, maize or milled soya. Further, the carrier may be a by-product of any of these materials.

Endoglucanases suitable for use in the present invention include those derived from bacterial sources, for example, *Bacillus* sp., including *Bacillus subtilis*, *Streptomyces* sp., *Clostridium* sp., including *Clostridium thermocellum* and *Clostridium cellulovorans*. Alternatively, fungal sources of cellulase are suitable. Suitable fungal sources include *Trichoderma* sp., *Trichoderma longibrachiatum*, *Trichoderma viride*, *Trichoderma koningii*, *Myceliophthora* sp., *Phanerochaete* sp., *Schizophyllum* sp., *Penicillium* sp., *Aspergillus* sp., *Geotricum* sp., *Fusarium* sp., *Fusarium oxysporum*, *Humicola* sp., *Humicola insolens*, and *Mucor* sp., including *Mucor miehei*.

Endoglucanase type components may not include components traditionally classified as endoglucanases using activity tests such as the ability of the component (a) to hydrolyze soluble cellulose derivatives such as carboxymethylcellulose (CMC), thereby reducing the viscosity of CMC containing solutions, (b) to readily hydrolyze hydrated forms of cellulose such as phosphoric acid, swollen cellulose (e.g., Walseth cellulose) and hydrolyze less readily the more highly crystalline forms of cellulose (e.g., Avicel, Solkafloc, etc.). On the other hand, it is believed that not all endoglucanase components, as defined by such activity tests, will enhance the nutritional value of feeds. Accordingly, it is more accurate for the purposes herein to define endoglucanase type components as those enzymes which

possess feed nutritional enhancement properties comparable to those possessed by the endoglucanase components of *Trichoderma longibrachiatum*.

Fungal cellulases can contain more than one endoglucanase type component. The different components generally have different isoelectric points, different molecular weights, different degrees of glycosylation, different substrate specificities, different enzymatic action patterns, etc. The different isoelectric points of the components allow for their separation via ion exchange chromatography and the like. In fact, the isolation of components from different sources is known in the art. See, for example Bjork et al., U.S. Patent No. 5,120,463; Schulein et al., International Application WO 89/09259; Wood et al., Biochemistry and Genetics of Cellulose Degradation, pp. 31-52 (1988); Wood et al., Carbohydrate Research, Vol. 190, pp. 279-297 (1989); and Schulein, Methods in Enzymology, Vol. 160, pp. 234-242 (1988). The entire disclosure of each of these references is incorporated herein by reference.

The term "EGI cellulase" refers to the endoglucanase component derived from *Trichoderma longibrachiatum* spp. characterized by a pH optimum of about 4.0 to 6.0, an isoelectric point (pI) of from about 4.5 to 4.7, and a molecular weight of about 47 to 49 Kdaltons. Preferably, EGI cellulase is derived from either *Trichoderma longibrachiatum* or from *Trichoderma viride*. EGI cellulase derived from *Trichoderma longibrachiatum* has a pH optimum of about 5.0, an isoelectric point (pI) of about 4.7 and a molecular weight of about 47 to 49

Kdaltons. EGI cellulase derived from *Trichoderma viride* has a pH optimum of about 5.0, an isoelectric point (pI) of about 5.3 and a molecular weight of about 50 Kdaltons.

It is noted that EGII has previously been referred to as "EGIII" by some authors but current nomenclature uses the term EGII. In any event the EGII protein differs substantially from the EGIII protein in its molecular weight, pI and pH optimum. The term "EGII cellulase" refers to the endoglucanase component derived from *Trichoderma spp.* characterized by a pH optimum of about 4.0 to 6.0, an isoelectric point (pI) of about 5.5, and a molecular weight of about 35 Kdaltons. Preferably, EGII cellulase is derived from either *Trichoderma longibrachiatum* or from *Trichoderma viride*.

The term "EGIII cellulase" refers to the endoglucanase component derived from *Trichoderma spp.* characterized by a pH optimum of about 5.0 to 7.0, an isoelectric point (pI) of from about 7.2 to 8.0, and a molecular weight of about 23 to 28 Kdaltons. Preferably, EGIII cellulase is derived from either *Trichoderma longibrachiatum* or from *Trichoderma viride*. EGIII cellulase derived from *Trichoderma longibrachiatum* has a pH optimum of about 5.5 to 6.0, an isoelectric point (pI) of about 7.4 and a molecular weight of about 25 to 28 Kdaltons. EGIII cellulase derived from *Trichoderma viride* has a pH optimum of about 5.5, an isoelectric point (pI) of about 7.7, and a molecular weight of about 23.5 Kdaltons.

"Exo-cellobiohydrolase type components" ("CBH type components") refers to all those cellulase components

which exhibit similar feed activity properties to CBHI and CBHII of *Trichoderma longibrachiatum*. In this regard, when used in combination with EG type components, CBHI and CBHII type components (as defined above) reduce the effectiveness of a cellulase supplement for animal feed in terms of the feed conversion ratio and/or feed digestibility.

Such exo-cellobiohydrolase type components may not include components traditionally classed as exo-cellobiohydrolases using activity tests such as those used to characterize CBHI and CBHII from *Trichoderma longibrachiatum*. For example, such components (a) are competitively inhibited by cellobiose (K; approximately 1mM); (b) are unable to hydrolyze to any significant degree substituted celluloses, such as carboxymethylcellulose, etc., and (c) hydrolyze phosphoric acid swollen cellulose and to a lesser degree highly crystalline cellulose. On the other hand, it is believed that some cellulase components which are characterized as CBH components by such activity tests, will enhance the nutritional value of feeds. Accordingly, it is believed to be more accurate for the purposes herein to define such exo-cellobiohydrolases as EG type components because these components possess similar functional properties in animal uses comparable to those of the endoglucanase components of *Trichoderma longibrachiatum*.

" β -glucosidase (BG) components" refer to those components of cellulase which exhibit BG activity; that is to say that such components will act from the non-reducing end

of cellobiose and other soluble cellooligosaccharides ("cellobiose") and give glucose as the sole product. BG components do not adsorb onto or react with cellulose polymers. Furthermore, such BG components are competitively inhibited by glucose (K_i approximately 1mM). While in a strict sense, BG components are not literally cellulases because they cannot degrade cellulose, such BG components are included within the definition of the cellulase system because these enzymes facilitate the overall degradation of cellulose by further degrading the inhibitory cellulose degradation products (particularly cellobiose) produced by the combined action of CBH components and EG components. Without the presence of BG components, moderate or little hydrolysis of crystalline cellulose will occur. BG components are often characterized by using aryl substrates such as p-nitrophenol- β -D-glucoside (PNPG) and thus are often called aryl-glucosidases. It should be noted that not all aryl-glucosidases are BG components, in that some do not hydrolyze cellobiose.

It is contemplated that the presence or absence of BG components in the cellulase composition can be used to regulate the activity of any CBH components in the composition. Specifically, because cellobiose is produced during cellulose degradation by CBH components, and because high concentrations of cellobiose are known to inhibit CBH activity, and further because such cellobiose is hydrolyzed to glucose by BG components, the absence of BG components in the cellulase composition will "turn-off" CBH activity when the concentration of cellobiose reaches inhibitory levels. It is also

contemplated that one or more additives (e.g., cellobiose, glucose, etc.) can be added to the cellulase composition to effectively "turn-off", directly or indirectly, some or all of the CBHI type activity as well as other CBH activity. When such additives are employed, the resulting composition is considered to be a composition suitable for use in this invention if the amount of additive is sufficient to lower the CBH type activity to levels equal to or less than the CBH type activity levels achieved by using the cellulase compositions described herein.

On the other hand, a cellulase composition containing added amounts of BG components may increase overall hydrolysis of cellulose if the level of cellobiose generated by the CBH components becomes restrictive of such overall hydrolysis in the absence of added BG components.

Methods to either increase or decrease the amount of BG components in the cellulase composition are disclosed in U.S. Serial No. 07/807,028 filed December 10, 1991 which is a continuation-in-part of U.S. Serial No. 07/625,140, filed December 10, 1990 (corresponding to EP-A-0 562 003), all of which are incorporated herein by reference in their entirety.

Fungal cellulases can contain more than one BG component. The different components generally have different isoelectric points which allow for their separation via ion exchange chromatography and the like. Either a

single BG component or a combination of BG components can be employed.

In a preferred embodiment, the endoglucanase components suitable for use in the present invention are those which exhibit properties similar to those obtainable from *Trichoderma longibrachiatum*, i.e., EGI, EGII and EGIII. Thus, the term "EG type components" refers to all of those cellulase components or combination of components which confer improved properties to feed in a manner similar to the endoglucanase components of *Trichoderma longibrachiatum*. In this regard, the endoglucanase components of *Trichoderma longibrachiatum* (specifically, EGI, EGII, EGIII and the like, either alone or in combination) impart characteristics such as improved feed conversion ratio, reduced gut viscosity and improved animal weight gain to animals fed grains treated with them as compared to untreated feed, or feed treated with whole cellulase. Methods for the preparation of EGI, EGII and EGIII are described in detail in WO 92/06209.

It is possible that components other than CBH type components present in the whole cellulase composition may cause undesirable gut viscosity, feed conversion ratio increase and lessened animal weight gain. Therefore, it is contemplated that the use of enriched endoglucanases, such as EGI, EGII or EGIII, may eliminate some or all of the problems which occur when whole cellulase is used.

It has been found that the inclusion of an endoglucanase enriched feed additive in a cereal-based diet of an animal enables the animal to digest the diet more efficiently. This is particularly the case in cereal-based feeds including barley where the presence of the above feed additive improves the feed conversion ratio and/or increases the digestibility of the cereal-based feed. Cereal-based feeds usually include at least 25% by weight of cereal and preferably at least 35% by weight. In addition to or instead of barley, the cereal may include one or more of wheat, triticale, rye and maize.

The endoglucanase enriched feed additives provided by the present invention also enable a conventional cereal-based feed to be modified by reducing its energy, and/or protein, and/or amino acid content whilst simultaneously maintaining the same nutritional levels of energy, protein, and amino acids available to the animal. This means that the amounts of costly energy and protein supplements conventionally included in an animal feed can be reduced as compared to conventional feeds. Energy supplements include fat. Protein supplements include fish-meal, wheat-meal, soya-bean, rapeseed, or canola. This results in a significant reduction in the cost per unit weight of the animal feed without decreasing its nutritional value. Alternatively, or even additionally, the amounts of amino acid supplements can be reduced as compared to conventional feeds which can also result in significant cost savings.

The enzyme feed additive according to the present invention can be prepared in a number of ways. For

instance, it can be prepared simply by mixing different enzymes having the appropriate activities to produce an enzyme mix. This enzyme mix can be either mixed directly with a feed, or more conventionally impregnated onto a cereal-based carrier material such as milled wheat, maize or soya flour. A by-product of any of these products may also be used. Such an impregnated carrier constitutes an enzyme feed additive in accordance with the third aspect of the present invention.

As an alternative, a cereal-based carrier formed from e.g. milled wheat or maize can be impregnated either simultaneously or sequentially with enzymes having the appropriate activities. For example, a milled wheat carrier may be sprayed with the one or more endoglucanases. Other enzymes may also be incorporated as appropriate. The carrier material impregnated with these enzymes also constitutes an enzyme feed additive in accordance with the third aspect of the present invention.

The feed additive provided by the present invention may be mixed directly with the animal feed, such as one comprising barley, to prepare the final feed. Alternatively, the feed additive may be mixed with one or more other feed additives such as a vitamin feed additive, a mineral feed additive and an amino acid feed additive. The resulting feed additive including several different types of components can then be mixed in an appropriate amount with the feed.

- 24 -

The resulting cereal-based feed preferably comprises 0.000001-0.1 g/kg of total endoglucanases, more preferably 0.00001-0.01 g/kg and most preferably 0.0001-0.001 g/kg.

The endoglucanases for use in the feed additive of the present invention can be obtained by growing a fungus such as a naturally occurring strain of *Trichoderma*. Thus, the fungus can be cultivated, after which it is removed from the broth. The cellulase enzyme complex can then be isolated from the broth and separated into its individual components from which the endoglucanases are in turn isolated. This technique is however not so preferred because of the purification steps necessary.

A more preferred method of preparing the enzyme feed additive of the present invention is to construct by genetic manipulation a host microorganism, such as the fungus *Trichoderma*, which produces the desired enzymes in the appropriate relative amounts. This can be done for instance by increasing the copy number of the gene encoding endoglucanases (e.g. EGI, EGII and/or EGIII) and/or by using a suitably strong promoter in front of any of the above endoglucanase genes. Alternatively or additionally the host strain can be deleted for certain cellulase genes (e.g. those encoding CBHI and/or CBHII). Such procedures are fully explained in the disclosure of WO 92/06209 in the case of transforming *T. reesei*.

The enzyme feed additive provided by the present invention may also include other enzymes such as xylanase, protease, α -amylase, glucoamylase, lipase,

- 25 -

pectinase, mannanase, α -galactosidase, α -arabinofuranosidase or phytase. Enzymes having the desired activities may for instance be mixed with the endoglucanases used in the present invention either before impregnating these on a cereal-based carrier or alternatively such enzymes may be impregnated simultaneously or sequentially on such a cereal-based carrier. The carrier is then in turn mixed with a cereal-based feed to prepare the final feed. It is also possible to formulate the enzyme feed additive as a solution of the individual enzyme activities and then mix this solution with a feed material pre-formed as pellets or as a mash.

It is also possible to include the enzyme feed additive in the animals' diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that the enzyme mix provided by the present invention is incorporated into the cereal-based food itself, although such incorporation forms a particularly preferred aspect of the present invention.

In one preferred embodiment, the xylanase added as an additional enzyme is the high pI xylanase and/or the low pI xylanase obtainable from *T. longibrachiatum* obtainable by the method of Example 22 of WO 92/06209. It is particularly preferred that the xylanase is the high pI xylanase.

According to a further preferred embodiment, the protease added as an additional enzyme is a subtilisin or mutant

- 26 -

thereof derived from the genus *Bacillus*. Suitable strains of *Bacillus* include but are not limited to *B. amyloliquefaciens*, *B. lentus*, *B. licheniformis*, *B. subtilis*, or *B. alcalophilus*.

The subtilisin may also be a mutant subtilisin having an amino acid sequence not found in nature but which is derived from a precursor subtilisin by inserting, deleting or replacing one or more different amino acid residues in the precursor subtilisin. Suitable mutant subtilisins are described in EP-A-0 130 756 corresponding to US-Re-34686 (including mutations at positions +155, +104, +222, +166, +133, +169, +189, +217, +156, +152); EP-A-0 251 446; WO 91/06637 etc. The most preferred subtilisin is a mutant subtilisin which comprises a substitution at the amino acid residue position equivalent to tyr+217 of *B. amyloliquefaciens* subtilisin with leucine.

Methods of producing such mutant subtilisins are described in detail in the publications US-Re-34606 and EP-A-0 251 446.

The cereal-based animal feeds including the additive of the present invention are suitable for animals such as pigs, ruminants such as sheep and cows, and poultry such as chickens, turkeys, geese and ducks. The feeds though are particularly suitable for poultry and pigs, and in particular broiler chickens.

As previously mentioned, the enzyme feed additive according to the present invention is preferably obtained

by growing a genetically modified strain of the fungus *Trichoderma*. This is because of its well known capacity to secrete whole cellulases in large quantities. This modified strain may be derived from *T. longibrachiatum*, *T. reesei* or *T. viride*. The genome of such strains can be modified to over-express or delete one or more of the enzyme components making up whole cellulase.

Microorganism cultures are grown to a stationary phase, filtered to remove the cells and the remaining supernatant is concentrated by ultrafiltration to obtain the endoglucanase or derivative thereof.

In a particular aspect of the above method, the medium used to cultivate the transformed host cells may be any medium suitable for endoglucanase production in *Trichoderma*. The endoglucanase or derivative thereof is recovered from the medium by conventional techniques including separation of the cells from the medium by centrifugation, or filtration, precipitation of the proteins in the supernatant or filtrate with salt, for example, ammonium sulphate, followed by chromatography procedures such as ion exchange chromatography, affinity chromatography and the like.

Alternatively, the final protein product may be isolated and purified by binding to a polysaccharide substrate or antibody matrix. The antibodies (polyclonal or monoclonal) may be raised against endoglucanase core domain peptides, or synthetic peptides may be prepared from portions of the core domain and used to raise polyclonal antibodies.

- 28 -

It is further contemplated by the present invention that the DNA fragment or variant DNA fragment encoding the endoglucanase or derivative may be functionally attached to a fungal promoter sequence, for example, the promoter of the *cbh1* or *egl* gene. Also contemplated by the present invention is manipulation of the *Trichoderma* strain via transformation such that a DNA fragment encoding an endoglucanase or derivative thereof is inserted within the genome. It is also contemplated that more than one copy of an endoglucanase DNA fragment or DNA variant fragment may be recombined into the strain.

A selectable marker must first be chosen so as to enable detection of the transformed fungus. Any selectable marker gene which is expressed in *Trichoderma* can be used in the present invention so that its presence in the transformants will not materially affect the properties thereof. The selectable marker can be a gene which encodes an assayable product. The selectable marker may be a functional copy of a *Trichoderma* gene which if lacking in the host strain results in the host strain displaying an auxotrophic phenotype.

The host strains used could be derivatives of *Trichoderma* which lack or have a non-functional gene or genes corresponding to the selectable marker chosen. For example, if the selectable marker of *pyr4* is chosen, then a specific *pyr* derivative strain is used as a recipient in the transformation procedure. Other examples of selectable markers that can be used in the present

invention include the *Trichoderma* genes equivalent to the *Aspergillus nidulans* genes *argB*, *trpC*, *niaD* and the like. The corresponding recipient strain must therefore be a derivative strain such as *argB*⁻, *trpC*⁻, *niaD*⁻, and the like.

The strain is derived from a starting host strain which is any *Trichoderma* strain. However, it is preferable to use a *T. longibrachiatum* cellulase over-producing strain such as RL-P37, described by Sheir-Neiss et al. in Appl. Microbiol. Biotechnology, 20 (1984) pp. 46-53, since this strain secretes elevated amounts of cellulase enzymes. This strain is then used to produce the derivative strains used in the transformation process.

The derivative strain of *Trichoderma* can be prepared by a number of techniques known in the art. An example is the production of *pyr4*⁻ derivative strains by subjecting the strains to fluoro-orotic acid (FOA). The *pyr4* gene encodes orotidine-5'-monophosphate decarboxylase, an enzyme required for the biosynthesis of uridine. Strains with an intact *pyr4* gene grow in a medium lacking uridine but are sensitive to fluoro-orotic acid. It is possible to select *pyr4*⁻ derivative strains which lack a functional orotidine monophosphate decarboxylase enzyme and require uridine for growth by selecting for FOA resistance. Using the FOA selection technique, it is also possible to obtain uridine requiring strains which lack a functional orotate pyrophosphoribosyl transferase. It is possible to transform these cells with a functional copy of the gene encoding this enzyme (Berges and Barreau, 1991, Curr. Genet. 19 pp359-365). Since it is easy to select

derivative strains using the FOA resistance technique in the present invention, it is preferable to use the *pyr4* gene as a selectable marker.

In a preferred embodiment of the present invention, *Trichoderma* host cell strains are deleted of one or more cellobiohydrolase genes prior to introduction of a DNA construct or plasmid containing the DNA fragment encoding the endoglucanase of interest. It is preferable to express an endoglucanase, derivative thereof or covalently linked endoglucanase domain derivative in a host that is missing one or more cellobiohydrolase genes in order to simplify the identification and subsequent purification procedures. Any gene from *Trichoderma* which has been cloned can be deleted such as *cbh1* or *cbh2*.

The desired gene that is to be deleted from the transformant is inserted into a plasmid by methods known in the art. This plasmid is selected such that unique restriction enzyme sites are present therein to enable the fragment of *Trichoderma* DNA to be subsequently removed as a single linear piece. The plasmid containing the gene to be deleted or disrupted is then cut at appropriate restriction enzyme site(s), internal to the coding region, the gene coding sequence or part thereof may be removed therefrom and the selectable marker (e.g. *pyr 4*) inserted. Flanking DNA sequences from the locus of the gene to be deleted or disrupted, preferably between about 0.5 to 2.0 kb, remain on either side of the selectable marker gene.

A single DNA fragment containing the deletion construct is then isolated from the plasmid and used to transform the appropriate *pyr⁻* *Trichoderma* host. Transformants are selected based on their ability to express the *pyr4* gene product and thus complement the uridine auxotrophy of the host strain. Southern blot analysis is then carried out on the resultant transformants to identify and confirm a double cross-over integration event which replaces part or all of the coding region of the gene to be deleted with the *pyr4* selectable markers.

Although specific plasmid vectors are described above, the present invention is not limited to the production of these vectors. Various genes can be deleted and replaced in the *Trichoderma* strain using the above techniques. Any available selectable markers can be used, as discussed above. Potentially any *Trichoderma* gene which has been cloned, and thus identified, can be deleted from the genome using the above-described strategy.

The expression vector of the present invention carrying the inserted DNA fragment or variant DNA fragment encoding the endoglucanase or derivative thereof of the present invention may be any vector which is capable of replicating autonomously in a given host organism, typically a plasmid. In preferred embodiments two types of expression vectors for obtaining expression of genes or truncations thereof are contemplated. The first contains DNA sequences in which the promoter, gene coding region, and terminator sequence all originate from the gene to be expressed. Gene truncation if required is obtained by deleting away the undesired DNA sequences

(coding for unwanted domains) to leave the domain to be expressed under control of its own transcriptional and translational regulatory sequences. A selectable marker is also contained on the vector allowing the selection for integration into the host of multiple copies of the novel gene sequences.

For example, a DNA construct which can be termed pEGID3'pyr contains the EGI cellulase core domain under the control of the EGI promoter, terminator, and signal sequences. The 3' end on the EGI coding region containing the cellulose binding domain has been deleted. The plasmid also contains the pyr4 gene for the purpose of selection.

The second type of expression vector is preassembled and contains sequences required for high level transcription and a selectable marker. It is contemplated that the coding region for a gene or part thereof can be inserted into this general purpose expression vector such that it is under the transcriptional control of the expression cassette's promoter and terminator sequences.

For example, pTEX is such a general purpose expression vector. Genes or part thereof can be inserted downstream of the strong CBHI promoter.

In the vector, the DNA sequence encoding the endoglucanase should be operably linked to transcriptional and translational sequences, i.e., a suitable promoter sequence and signal sequence in reading frame to the structural gene. The promoter may be any

DNA sequence which shows transcriptional activity in the host cell and may be derived from genes encoding proteins either homologous or heterologous to the host cell. The signal peptide provides for extracellular expression of the endoglucanase or derivatives thereof. The DNA signal sequence is preferably the signal sequence naturally associated with the truncated gene to be expressed, however the signal sequence from any endoglucanase is contemplated in the present invention.

The procedures used to ligate the DNA sequences coding for the truncated endoglucanases or derivatives thereof with the promoter, and insertion into suitable vectors containing the necessary information for replication in the host cell are well known in the art.

The DNA vector or construct described above may be introduced in the host cell in accordance with known techniques such as transformation, transfection, microinjection, microporation, biolistic bombardment and the like.

In a preferred embodiment of the present invention, the modified strain is derived from *Trichoderma* sp. containing deleted or disrupted genes for CBHI and/or CBHII thereby being unable to produce catalytically active cellobiohydrolase. The cellulase enzymes produced by such an organism will be enriched in endoglucanases and include no more than 20% cellobiohydrolases based upon the combined weight of cellulase proteins which it produces. It is particularly preferred that the modified strain is unable to produce catalytically active CBHI as

this enzyme forms the greatest proportion of any component of whole cellulase from *Trichoderma sp.* In instances where only production of EGI is desired, it is further preferred that such a modified strain contains deleted or disrupted genes for EGI and EGII so as to be unable to produce catalytically active EGI and/or EGII.

Alternatively, the modified strain can additionally contain recombinant DNA allowing expression and secretion of truncated catalytic cores of either EGI or EGII. While not wishing to be bound by theory, it is believed that the presence of a cellulose binding domain on a cellulase may be responsible for certain undesirable properties observed when animals are fed feed supplemented with cellulase, e.g. increased gut viscosity. Accordingly, by removing the cellulose binding domain and retaining an intact cellulase core, it is possible to limit or eliminate these properties.

Before describing methods of producing such truncated endoglucanases, the following provides a detailed description of the drawings which is necessary to understand these production techniques.

Figure 1 depicts the genomic DNA and amino acid sequence of EGI. The signal sequence begins at base pair 113 and ends at base pair 178 (Seq ID No. 13). The catalytic core domain begins at base pair 179 through 882 of exon one, and base pair 963 through base pair 1379 of the second exon (Seq ID No. 5). The linker region begins at base pair 1380 and ends at base pair 1460 (Seq ID No. 9). The cellulose binding domain begins at base pair 1461 and

ends at base pair 1616 (Seq ID No. 1). Seq ID Nos. 14, 6, 10 and 2 represent the amino acid sequence of EGI signal sequence, catalytic core domain, linker region and binding domain, respectively.

Figure 2 depicts the genomic DNA and amino acid sequence of EGII. The signal sequence begins at base pair 262 and ends at base pair 324 (Seq ID No. 15). The cellulose binding domain begins at base pair 325 and ends at base pair 432 (Seq ID No. 3). The linker region begins at base pair 433 and ends at base pair 534 (Seq No. 11). The catalytic core domain begins at base pair 535 through base pair 590 in exon one, and base pair 765 through base pair 1689 in exon two (Seq ID No. 7). Seq ID Nos. 16, 4, 12 and 8 represent the amino acid sequence of EGII signal sequence, binding domain, linker region and catalytic core domain, respectively.

Figure 3 depicts the genomic DNA and amino acid sequence of EGIII. The signal sequence begins at base pair 151 and ends at base pair 198 (Seq ID No. 19). The catalytic core domain begins at base pair 199 through base pair 557 in exon one, base pair 613 through base pair 833 in exon two and base pair 900 through base pair 973 in exon three (Seq ID No. 17). Seq ID Nos. 20 and 18 represent the amino acid sequence of EGIII signal sequence and catalytic core domain, respectively.

Figure 4 illustrates the construction of EGI core domain expression vector (Seq ID No. 21).

Figure 5 is a graph demonstrating the initial viscosity-reducing activity of whole cellulase and various enriched endoglucanase preparations at different pHs.

As mentioned above, the one or more endoglucanases present in the enzyme feed additive of the present invention may be truncated EG derivatives such as EGI which lacks the cellulose binding domain (which can be termed EGIcore) and/or EGII also lacking the cellulose binding domain. These derivatives are prepared by recombinant methods by transforming into a host cell, a DNA construct comprising at least a fragment of DNA encoding a portion or all of the core region of the endoglucanases, for example, EGI or EGII functionally attached to a promoter, growing the host cell to express the truncated endoglucanase, derivative of truncated endoglucanase or covalently linked truncated endoglucanase domain derivatives of interest. The resulting truncated endoglucanase can be used once separated from the microorganism cells as a feed additive. As an alternative, the truncated endoglucanase, or derivative thereof may in addition be purified to substantial homogeneity prior to use.

The following Reference Examples 1 and 2 are provided in order to illustrate techniques for producing endoglucanase enriched enzyme compositions by transforming and growing genetically modified microorganisms.

Reference Example 1.

Cloning and Expression of EG1 Core Domain Using its Own Promoter, Terminator and Signal Sequence.

Part 1. Cloning.

The complete *egl1* gene used in the construction of the EG1 core domain expression plasmid, pEG1D3'pyr, was obtained from the plasmid pUC218::EG1. (See FIG.4.) The 3' terminator region of *egl1* was ligated into pUC218 (Korman, D. et al Curr Genet 17:203-212, 1990) as a 300 bp BsmI-EcoRI fragment (the BsmI site is at 46 bp 3' of the *egl1* stop codon) along with a synthetic linker designed to replace and cellulose binding domain of *egl1* with a stop codon and continue with the first 46 bp of the *egl1* terminator sequence. The resultant plasmid, pEG1T, was digested with HindIII and BsmI and the vector fragment with the *egl1* terminator was isolated from the digest by agarose gel electrophoresis followed by electroelution. The *egl1* gene promoter sequence and core domain of *egl1* were isolated from pUC218::EG1 as a 2.3kb HindIII-SstI fragment and ligated with the same synthetic linker fragment and the HindIII-BsmI digested pEG1T to form pEG1D3'

The net result of these operations is to replace the 3' intron and cellulose binding domain of *egl1* with synthetic oligonucleotides of 53 and 55nt. These place a TAG stop

codon after serine 415 and thereafter continued with the *egl1* terminator up to the *BsmI* site.

Next, the *T. longibrachiatum* selectable marker, *pyr4*, was obtained from a previous clone p219M (Smith et al 1991), as an isolated 1.6kb *EcoRI*-*HindIII* fragment. This was incorporated into the final expression plasmid, pEG1D3'*pyr*, in a three way ligation with pUC18 plasmid digested with *EcoRI* and dephosphorylated using calf alkaline phosphatase and a *HindIII*-*EcoRI* fragment containing the *egl1* core domain from pEG1D3'.

Part 2. Transformation and Expression.

A large scale DNA prep was made of pEG1D3'*pyr* and from this the *EcoRI* fragment containing the *egl1* core domain and *pyr4* gene was isolated by preparative gel electrophoresis. The isolated fragment was transformed into a strain (1A52*pyr13*) in which the *cbh1*, *cbh2*, *egl1* and *egl2* genes had been deleted and which was *pyr4*⁻ (described in WO 92/06209) and stable transformants were identified.

To select which transformants expressed *egl1* core domain the transformants were grown up in shake flasks under conditions that favored induction of the cellulase genes (Vogel's medium + 1% lactose). After 4-5 days of growth, protein from the supernatants was concentrated and either 1) run on SDS polyacrylamide gels prior to detection of the EGI core domain by Western analysis using anti-EGI polyclonal antibodies or 2) the concentrated supernatants

were assayed directly using Remazol Brilliant Blue (RBB) carboxy methyl cellulose as an endoglucanase specific substrate and the results compared to the parental strain (1A52) as a control. Transformant candidates were identified as possibly producing a truncated EGI core domain protein. Genomic DNA and total mRNA was isolated from these strains following growth on Vogels + 1% lactose and Southern and Northern blot experiments performed using an isolated DNA fragment containing only the *egl1* core domain. These experiments demonstrated that transformants could be isolated having a copy of the *egl1* core domain expression cassette integrated into the genome of 1A52 and that these same transformants produced *egl1* core domain mRNA.

One transformant was then grown using media suitable for cellulase production in *Trichoderma* well known in the art that was supplemented with lactose (Warzymoda, M. et al 1984 French Patent No. 2555603) in a 14L fermentor. The resultant broth was concentrated and the proteins contained therein were separated by SDS polyacrylamide gel electrophoresis and the EGI core domain protein identified by Western analysis. It was subsequently estimated that the protein concentration of the fermentation supernatant was about 5-6 g/L of which approximately 1.7-4.4g/L was EGI core domain based on CMCase activity. This value is based on an average of several EGI core fermentations that were performed.

In a similar manner, any other endoglucanase whether truncated or not or derivative thereof may be produced by

procedures similar to those discussed above. Thus production of EGI can be achieved by using similar techniques except that deletion of the cellulose binding domain is omitted. Corresponding techniques can be used to produce complete EGII, EGIII, and EGII from which the cellulose binding domain is omitted.

Reference Example 2.

Purification of EGI and EGII catalytic cores

Part 1. EGI catalytic core

The EGI core was purified in the following manner. The concentrated (UF) broth was diluted to 14 mg/ml in 23 mM Na Acetate pH 5.0. Two hundred grams of avicel cellulose gel (FMC Bioproducts, Type PH-101) was added to the diluted EGI core broth and mixed at room temperature for forty five minutes. The avicel was removed from the broth by centrifugation, resulting in an enriched EGI core solution. This solution was then buffer exchanged into 10 mM TES pH 7.5 using an Amicon stirred cell concentrator with a PM 10 membrane (diaflo ultra filtration membranes, Amicon Cat # 13132MEM 5468A). The EGI core sample was then loaded onto an anion exchange column (Q-sepharose fast flow, Pharmacia Cat # 17-0510-01) and eluted in a salt gradient from 0 to 0.5M NaCl in 10 mM TES pH 7.5. The fractions which contained the EGI core were combined and concentrated using the Amicon stirred cell concentrator mentioned above.

Part 2. EGII catalytic core

It is contemplated that the purification of the EGII catalytic core is similar to that of EGII cellulase because of its similar biochemical properties. The theoretical pI of the EGII core is less than a half a pH unit lower than that of EGII. Also, EGII core is approximately 80% of the molecular weight of EGII. Therefore, the following purification protocol is based on the purification of EGII. The method may involve filtering the UF concentrated broth through diatomaceous earth and adding $(\text{NH}_4)_2\text{SO}_4$ to bring the solution to 1M $(\text{NH}_4)_2\text{SO}_4$. This solution may then be loaded onto a hydrophobic column (phenyl-sepharose fast flow, Pharmacia, cat #17-0965-02) and the EGII may be step eluted with 0.15 M $(\text{NH}_4)_2\text{SO}_4$. The fractions containing the EGII core may then be buffer exchanged into citrate-phosphate pH 7, 0.18 mOsm. This material may then be loaded onto a anion exchange column (Q-sepharose fast flow, Pharmacia, cat. #17-0510-01) equilibrated in the above citrate-phosphate buffer. It is expected that EGII core will not bind to the column and thus be collected in the flow through.

The present invention will be explained in more detail by way of the following further Reference Example 3 and Example 1. In the Example 1, reference is made to units of β -glucanase activity. This activity is measured by the following assay.

One unit of β -glucanase activity is the amount of enzyme which liberates one μmol of reducing sugars (expressed as

glucose equivalents) from the substrate in one minute under the conditions described.

Reagents 1. 1.0% (w/v) β -glucan substrate

Moisten 1.0 g of mixed-linked β -(1,3)(1,4)-glucan (Biocon Biochemicals Ltd.) with 10 ml of ethanol. Add about 80 ml of distilled water and warm up to boil. Continue boiling with vigorous stirring until β -glucan is dissolved and a turbid solution is obtained. Cool the turbid solution to room temperature continuously stirring and adjust the β -glucan concentration to 1.0% (w/w) by adding distilled water. Filter through a glass fibre filter paper.

The substrate can be used immediately. The substrate is usable for two days if stored in a cold room.

2. 0.1 M sodium acetate buffer, pH 5.0

A. Dissolve 8.2 g of anhydrous sodium acetate in distilled water and fill to 1000 ml with distilled water.

B. Dissolve 6.0 g of glacial acetic acid in distilled water and fill to 1000 ml with distilled water.

Adjust the pH of solution A to 5.0 with solution B.

3. Dinitrosalicylic acid (DNS) reagent

Suspend 20.0 g of 3,5-dinitrosalicylic acid in about 800 ml of distilled water. Add gradually 300 ml of sodium hydroxide solution (32.0 g of NaOH in 300 ml of distilled water) while stirring continuously. Warm the suspension in a water bath (the temperature may not exceed +48°C) while stirring until the solution is clear. Add gradually 600 g of potassium sodium tartrate. Warm the solution (the temperature may not exceed +48°C) if needed until solution is clear.

Fill to 2000 ml with distilled water and filter through a coarse sintered glass filter.

Store in a dark bottle at room temperature. The reagent is stable for a maximum of 6 months.

Procedure1. Enzyme sample

Equilibrate 1 ml of enzyme dilution (in 0.1 M sodium acetate buffer, pH 5.0) at +30°C. Add 1 ml of β -glucan substrate, stir and incubate at +30°C for exactly 10

- 44 -

minutes. Add 3 ml of DNS-reagent, stir and boil the reaction mixture for exactly 5 minutes. Cool the reaction mixture in a cold water bath to room temperature and measure the absorbance at 540 nm against distilled water.

2. Enzyme blank

Incubate 1 ml of β -glucan substrate at +30°C for 10 minutes. Add 3 ml of DNS-solution and stir. Add 1 ml of enzyme dilution (in 0.1 M sodium acetate buffer, pH 5.0) and stir. Boil the mixture for exactly 5 minutes. Cool the reaction mixture in cold water bath to room temperature and measure the absorbance at 540 nm against distilled water.

The absorbance difference between the enzyme sample and the enzyme blank should be 0.3-0.5.

3. Standard curve

Prepare standard solutions from anhydrous glucose in distilled water. Glucose concentration in the standards should be 0.1-0.6 mg/ml. Pipette 1 ml of glucose standard solution, 1 ml of distilled water and 3 ml of DNS-reagent into a test tube. Stir and boil for exactly 5

- 45 -

minutes. Cool in a cold water bath to room temperature and measure the absorbance at 540 nm against standard blank. In the standard blank, glucose solution is replaced by 1 ml of distilled water. Otherwise standard blank is treated like glucose standard.

Plot glucose concentration as a function of absorbance. New standard curve is prepared for every new DNS-reagent.

Calculation

The β -glucanase activity of the sample is calculated according to the following equation:

$$\text{Activity (U/g)} = \frac{([A(X) - A(O)] \times k + C) \times 1000 \times Df}{MW_{glu} \times t}$$

wherein:

- A(X) = absorbance of the enzyme sample
- A(O) = absorbance of the enzyme blank
- k = the slope of the standard curve
- C = the intercept of glucose standard curve
- 1000 = factor, mmol \rightarrow μ mol
- Df = dilution factor (ml/g)
- MW_{glu} = molecular weight of glucose (180.16 mg/mmol)
- t = reaction time (10 minutes)

The Reference Example 3 makes reference to the measurement of the viscosity reducing activity of β -

glucanase. This activity is measured by the following assay.

Principle β -glucanase catalyses the hydrolysis of β -glucan which results in reduction of viscosity of β -glucan solution. Reciprocal specific viscosity as a function of time is linear function at the initial moment of the reaction. Using the slope of the linear curve β -glucanase activity can be determined. Reciprocal specific viscosity is determined using a capillary viscosimeter.

Apparatus Ostwald capillary viscosimeter (Brand, No 11, 75-100 sec)

Water bath controlled at 30 °C

Magnetic stirrer

Stop Watch

Glassinter filters no 3 and 4

Magnetic stirrer with hotplate

Reagents 1. 0.5 M acetate buffer, pH 4.0

Dilute 30 g of glacial acetic acid (BDH AnalaR 10001) into 900 ml of distilled water. Adjust the pH to 4.0 with 2.5 g of NaOH (Merck 6498). Fill with distilled water into 1000 ml.

- 47 -

2. 0.05 M acetate buffer, pH 4.0

Dilute 100 ml of 0.5 M acetate buffer, pH 4.0 into 800 ml of distilled water. Adjust pH if needed to 4.0 with 1 M NaOH or glacial acetic acid. Fill to 1000 ml with distilled water. Filtrate through glassinter filter no 4.

3. β -glucan solution

Weigh 1.0 g mixed-linked β -(1,3)(1,4)-glucan (Biocon Biochemicals) in a tared beaker. Add approx. 6 ml of ethanol and mix with metallic mixing rod until the mixed-linked β -glucan has become totally wet. Add approx. 80 ml of distilled water, mix with magnetic stirrer and warm up solution to boil. Keep boiling until the mixed-linked β -glucan has totally dissolved. Ensure that there is no material on the walls of the beaker. Cool the solution to room temperature while continuously stirring. Add 10 ml of 0.5 M acetate buffer, pH 4.0. If needed adjust pH to 4.0 with 1 M NaOH or glacial acetic acid. Add distilled water until the total weight of the substrate solution is 100 g. Filtrate with glassinter filter no 3. Store the substrate solution maximum for two days at +4 °C.

Procedure 1. Determination of reciprocal specific viscosity

Before activity determination ensure that viscosimeter is clean by rinsing with distilled water and acetone (in this sequence). Dry the viscosimeter by removing acetone with compressed air or in vacuum.

All samples, substrate solution and viscosimeter have to be equilibrated at 30 °C for at least 15 minutes before determination.

Reciprocal specific viscosity follows equation 1

$$1/\mu_{sp} = \frac{dT_0}{dT_s - dT_0} \quad (\text{Equation 1})$$

whereas

$1/\mu_{sp}$ = reciprocal specific viscosity
 dT_0 = falling-time of acetate buffer (in seconds)
 dT_s = falling-time of sample solution (in seconds)

The falling-time for solutions follow equation 2

$$dT_i = T_2 - T_1 - h \quad (\text{Equation 2})$$

where

dT_i = falling-time of solutions
 $T_2 - T_1$ = time used by the solution to fall between upper and lower marks in the capillary (in seconds)
 h = Hagenbach factor

Hagenbach factors:

| Falling-time (dT_i) s | h |
|------------------------------|-----|
| <hr/> | |
| < 54.2 | 1.0 |
| 54.3 - 57.3 | 0.9 |
| 57.4 - 60.5 | 0.8 |
| 60.6 - 65.5 | 0.7 |
| 65.6 - 70.8 | 0.6 |
| 70.9 - 78.5 | 0.5 |
| 78.6 - 88.9 | 0.4 |
| 89.0 - 105 | 0.3 |
| 105 - 135 | 0.2 |
| 135 - 240 | 0.1 |
| > 240 | 0 |

Start the determination of the falling-time with a clean and dry viscosimeter by pumping 7.5 ml of solution to the capillary so that the surface of the solution exceeds the upper mark of the capillary. Determine with stop watch the time needed for the solution to fall between upper and lower marks in the capillary.

2. Determination of falling-time for acetate buffer

Determine the falling-time (dT_0) for 0.05 M acetate buffer, pH 4.0, as described above whenever β -glucanase activity is determined.

3. Adjustment of β -glucan solution

The initial reciprocal specific viscosity in the hydrolysis of β -glucan has to be 0.13. The viscosity in the β -glucan solution varies from batch to batch and this has to be compensated by varying the ratio of β -glucan solution and sample so that the initial viscosity is correct.

Make 5 different β -glucan/0.05 M acetate buffer, pH 4.0, mixtures by pipetting β -glucan (A) 5.0-6.5 ml and respectively 2.5-1.0 ml of 0.05 M acetate buffer, pH 4.0, to make the total volume of each mixture to be 7.5 ml. Determine the viscosities of these solutions and calculate the reciprocal specific viscosities.

Plot the reciprocal specific viscosity as a function of β -glucan. From the graph determine the amount of β -glucan that corresponds to a reciprocal specific viscosity value of 0.13. This β -glucan amount will be used later on in all β -glucanase activity determinations with this β -glucan solution.

Initial viscosity of β -glucan solution has to be determined whenever β -glucanase activity is determined.

4. Determination of β -glucanase activity

Pipette β -glucan volume (A) determined as described above to the test tube and equilibrate at 30 °C for at least 15 minutes. Add V ml ($V = 7.5 \text{ ml} - A$) of enzyme sample diluted in 0.05 M acetate buffer, pH 4.0 and equilibrated at 30 °C for at least 15 minutes. Start the stop watch. Mix the solution properly and transfer it to the viscosimeter. Determine falling-time dT_s 4-5 times during 20-30 minutes from the mixing of the solutions.

The determinations have to be done from at least two different dilutions and with at least 3 parallel determinations from each dilution. Proper dilution of the sample depends on enzyme mixture product and end feed to be assayed. The dilutions are indicated separately. For enzyme mixtures the total dilution factor is typically 1/2000-1/15000 and for end feeds 1/5-1/20.

Calculations Calculate the reciprocal specific viscosities according to equation 1. Plot the reciprocal specific viscosity as a function of hydrolysis time (in seconds).

β -glucanase activity is determined as an increase of reciprocal specific viscosity (IRV) in one minute, equation 3.

$$\beta\text{-glucanase activity (IRVU/g)} = \frac{k \times D \times 60}{V} \quad (\text{Equation 3})$$

where

k = slope of the curve
 D = total dilution factor
 60 = conversion factor, s \rightarrow min
 V = sample volume

Literature The Institute of Brewing (1979) J. Inst. Brew, 85, 92-94.

Analyse av β -glukanaseaktivitet ved viskosimetrisk metode, Norges Veterinærhøgskole.

Reference Example 3

The first trial which was undertaken was to compare the efficacy *in vitro* of several different cellulases having an enriched content of endoglucanases in comparison with whole cellulase. Thus, seven different enzyme preparations were prepared the first from naturally occurring *T. longibrachiatum* and the second-seventh from genetically modified strains thereof in accordance with the following Table 1:

- 53 -

Table 1

| Enzyme Preparation | Strain Genotype |
|--------------------|--|
| Whole cellulase | EGI ⁺ EGII ⁺ EGIII ⁺ CBHI ⁺ CBHII ⁺ |
| Enriched EGI | EGI ⁺⁺⁺ EGII ⁺ EGIII ⁺ CBHI ⁺ CBHII ⁺ |
| Enriched EGI.Acbd | EGI.Acbd ⁺ EGI ⁺ EGII ⁺ EGIII ⁺ CBHI ⁺ CBHII ⁺ |
| Enriched EGII | EGI ⁺ EGII ⁺⁺⁺ EGIII ⁺ CBHI ⁺ CBHII ⁺ |
| Enriched EGIII | EGI ⁺ EGII ⁺ EGIII ⁺ CBHI ⁺ CBHII ⁺ |
| Purified EGIII | EGI ⁺ EGII ⁺ EGIII ⁺ CBHI ⁺ CBHII ⁺ |

In the above Table 1, the strain producing enriched EGI contains multiple EGI encoding genes. Similarly, the strains producing enriched EGII and EGIII respectively contain multiple copies of the EGII and EGIII encoding genes.

The enriched EGI, enriched EGII, enriched EGIII and purified EGIII enzyme preparations were obtained by following the procedures described in PCT WO 92/06209. Purified EGIII was the same as enriched EGIII, except that the supernatant containing the secreted EGIII was subjected to the PEG purification procedure described in U.S. Patent No. 5,328,841 to remove xylanase activity. Truncated EGI core was produced according to the techniques described in Reference Example 1 and purified in accordance with Reference Example 2.

The viscosity reducing activity on soluble mixed-linked barley β -glucan was measured for each of the above enzyme

- 54 -

preparations in accordance with the assay described above.

The results of this testing are illustrated in the graph of Figure 5. Since *T. longibrachiatum* β -glucanase is dosed as a feed additive on the basis of activity measured by the DNS reducing sugar assay method, enzyme addition for the viscosity-reducing activity assay was standardised by this procedure.

The results illustrated in Figure 5 demonstrate that the viscosity-reducing activity of whole cellulase is significantly higher than that of each of the enriched endoglucanase preparations regardless of pH.

Example 1

Thirteen groups of broiler chickens, each initially including a minimum of 49 chickens, were fed with the barley-based feed set out in Table 2 between 8 and 21 days of age. Feed intake and body weight gain were measured between 8 and 21 days.

Table 2

| Ingredients | Percent | Weight |
|----------------|----------------|----------------|
| Barley | 58.56% | 585.63 |
| Soybean ml 48 | 31.63% | 316.26 |
| Soy oil | 6.07% | 60.65 |
| Salt | 0.29% | 2.90 |
| DL Methionine | 0.28% | 2.76 |
| Lysine HCl | 0.04% | 0.44 |
| Limestone | 1.41% | 14.06 |
| Dicalcium Phos | 1.23% | 12.31 |
| VIT/MIN | 0.50% | 5.00 |
| | | |
| TOTAL | 100.00% | 1000.00 |

The nutritional value of the above feed can be subjected to computer analysis using for example the programme "Format" available from Format International. This provides an analysis of the nutrient content of the feed including for example the expected nutritional levels of various metabolites. The results of such an analysis for the feed of Table 2 is set out in the following Table 3.

Barley-Based Diet

TABLE 3

| Nutrient | Target | Value |
|------------------|---------|---------|
| Crude protein % | 22.00 | 22.00 |
| Poult ME kcal/kg | 3000.00 | 3000.00 |
| Pig DE Kcal | | 3363.16 |
| Calcium % | 0.90 | 0.90 |
| Phos % | | 0.66 |
| Avail Phos % | 0.40 | 0.40 |
| Fat % | | 7.28 |
| Fibre % | | 4.00 |
| Met % | | 0.58 |
| Cys % | | 0.37 |
| Met + Cys % | 0.95 | 0.95 |
| Lys % | 1.25 | 1.25 |
| His % | | 0.52 |
| Tryp % | 0.24 | 0.30 |
| Thr % | 0.80 | 0.82 |
| Arg % | 1.40 | 1.44 |
| Iso % | | 1.01 |
| Leu % | | 1.59 |
| Phe % | | 1.11 |
| Val % | | 1.10 |
| Gly % | | 0.99 |
| Phe + Tyr % | | 1.89 |
| Na % | 0.15 | 0.15 |
| Cl % | | 0.29 |
| K % | | 0.96 |
| Linoleic acid % | 1.00 | 3.00 |
| Na + K + HCl | | 2.29 |

The barley-based feeds fed to twelve of the groups of chickens were supplemented by varying amounts of each of

the enzyme preparations set out in the above Table 1. Each of the enzyme preparations was tested at a β -glucanase activity concentration of 120 units/kg of the feed and 240 units/kg of the feed. The β -glucanase activity was measured using the β -glucanase activity assay described above. The diet of the thirteenth group, the control group, was not supplemented with any of the enzyme preparations.

Results of these various tests are set out in the following Tables 4 and 5. The results set out in Table 4 are for diets supplemented with 120 units of β -glucanase activity per kg of feed whereas the results set out in Table 5 are for feeds supplemented with 240 units of β -glucanase activity per kg of feed. The results set out in the Tables 4 and 5 provide the body weight gain, the feed conversion ratio and the viscosity in the gastrointestinal region of the various groups of broiler chickens. The results have been adjusted for mortality.

Table 4

| | <u>BWG(g)</u> | <u>FCR</u> | <u>Viscosity (cps)</u> |
|--------------------|---------------|------------|------------------------|
| Control | 329 | 1.72 | 15.3 |
| Enriched EGI | 358 | 1.60 | 12.6 |
| Enriched EGI.Ac bd | 437 | 1.42 | 10.5 |
| Enriched EGII | 396 | 1.50 | 13.6 |
| Enriched EGIII | 356 | 1.66 | 6.0 |
| Purified EGIII | 332 | 1.85 | 7.9 |
| Complete Cellulase | 381 | 1.62 | 10.3 |

Table 5

| | BWG (g) | FCR | Viscosity (cps) |
|----------------------------|---------|------|-----------------|
| Control | 329 | 1.72 | 15.3 |
| Enriched EGI | 376 | 1.60 | 14.5 |
| Enriched EGI. Δ cbd | 395 | 1.57 | 5.6 |
| Enriched EGII | 377 | 1.70 | 11.6 |
| Enriched EGIII | 423 | 1.54 | 8.1 |
| Purified EGIII | 401 | 1.56 | 7.7 |
| Complete Cellulase | 404 | 1.66 | 6.4 |

From the above results, it can be seen that the body weight gain, feed conversion ratio and viscosity for the control group without enzyme supplementation were relatively poor. In comparison with the results for whole cellulase, enriched EGI is more effective in terms of FCR when used at a dosage of 240 units/kg of feed. The same is also true for enriched EGIII and purified EGIII. On the other hand, enriched EGII provides superior results at 120 units/kg of feed. Finally, the most preferred enzyme preparation, which is the enriched EGI. Δ cbd provides superior results at both 120 and 240 units/kg of feed. This enzyme preparation deleted for the cellulose binding domain provides superior results at both concentrations tested as compared to enriched natural type EGI. These results also strongly suggest that the different enzyme preparations have different dose optima in terms of their effects on body weight gain and feed conversion ratios.

By comparing the results of Reference Example 3 and Example 1, it can be seen that different results are obtained between *in vitro* and *in vivo* testing. Thus, in

the *in vitro* testing of Reference Example 3, the viscosity reducing activity of whole cellulase was higher than that for the enriched preparations of EGI, EGII, EGIII and EGI. Δ cbd.

In contrast, the *in vivo* test results of Example 1 indicate that each of the enzyme preparations tested has at least one advantageous characteristic of improved body weight gain, feed conversion ratio and/or reduced viscosity in the gastrointestinal region as compared to whole cellulase at both concentrations tested. The preferred enzyme preparations are EGI. Δ cbd and EGIII.

The effects demonstrated above of reducing feed conversion ratios and/or gastrointestinal viscosities can also be obtained when feeds prepared in accordance with the present invention but based upon other cereals such as wheat, triticale, rye and maize are fed to other animals such as turkeys, geese, ducks, pigs, sheep and cattle, as well as chickens.

- 59 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..82, 140..159)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| CAC | TGG | GGG | CAG | TGC | GGT | GGC | ATT | GGG | TAC | AGC | GGG | TGC | AAG | ACG | TGC | 48 |
| His | Trp | Gly | Gln | Cys | Gly | Gly | Ile | Gly | Tyr | Ser | Gly | Cys | Lys | Thr | Cys | |
| 1 | | | | 5 | | | | 10 | | | | | 15 | | | |

- 60 -

ACG TCG GGC ACT ACG TGC CAG TAT AGC AAC GAC T GTTCGTATCC 92

Thr Ser Gly Thr Thr Cys Gln Tyr Ser Asn Asp

20

25

CCATGCCTGA CGGGAGTGAT TTTGAGATGC TAACCGCTAA AATACAG AC TAC TCG 147

Tyr Tyr Ser

30

CAA TGC CTT TA 159

Gln Cys Leu

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

His Trp Gly Gln Cys Gly Gly Ile Gly Tyr Ser Gly Cys Lys Thr Cys

1

5

10

15

Thr Ser Gly Thr Thr Cys Gln Tyr Ser Asn Asp Tyr Tyr Ser Gln Cys

20

25

30

Leu

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..108

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CAG CAG ACT GTC TGG GGC CAG TGT GGA GGT ATT GGT TGG AGC GGA CCT 48
Gln Gln Thr Val Trp Gly Gln Cys Gly Gly Ile Gly Trp Ser Gly Pro
1 5 10 15

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| ACG | AAT | TGT | GCT | CCT | GGC | TCA | GCT | TGT | TCG | ACC | CTC | AAT | CCT | TAT | TAT | 96 |
| Thr | Asn | Cys | Ala | Pro | Gly | Ser | Ala | Cys | Ser | Thr | Leu | Asn | Pro | Tyr | Tyr | |
| | | | 20 | | | | 25 | | | | | 30 | | | | |

GCG CAA TGT ATT 108

Ala Gln Cys Ile

35

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gln Gln Thr Val Trp Gly Gln Cys Gly Gly Ile Gly Trp Ser Gly Pro

1 5 10 15

- 62 -

Thr Asn Cys Ala Pro Gly Ser Ala Cys Ser Thr Leu Asn Pro Tyr Tyr
 20 25 30
 Ala Gln Cys Ile
 35

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1201 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..704, 775..1201)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

| | |
|--|-----|
| CAG CAA CCG GGT ACC AGC ACC CCC GAG GTC CAT CCC AAG TTG ACA ACC | 48 |
| Gln Gln Pro Gly Thr Ser Thr Pro Glu Val His Pro Lys Leu Thr Thr | |
| 1 5 10 15 | |
| TAC AAG TGT ACA AAG TCC GGG GGG TGC GTG GCC CAG GAC ACC TCG GTG | 96 |
| Tyr Lys Cys Thr Lys Ser Gly Gly Cys Val Ala Gln Asp Thr Ser Val | |
| 20 25 30 | |
| GTC CTT GAC TGG AAC TAC CGC TGG ATG CAC GAC GCA AAC TAC AAC TCG | 144 |
| Val Leu Asp Trp Asn Tyr Arg Trp Met His Asp Ala Asn Tyr Asn Ser | |
| 35 40 45 | |
| TGC ACC GTC AAC GGC GGC GTC AAC ACC ACG CTC TGC CCT GAC GAG GCG | 192 |

- 63 -

Cys Thr Val Asn Gly Gly Val Asn Thr Thr Leu Cys Pro Asp Glu Ala

50

55

60

ACC TGT GGC AAG AAC TGC TTC ATC GAG GGC GTC GAC TAC GCC GCC TCG 240

Thr Cys Gly Lys Asn Cys Phe Ile Glu Gly Val Asp Tyr Ala Ala Ser

65

70

75

80

GGC GTC ACG ACC TCG GGC AGC AGC CTC ACC ATG AAC CAG TAC ATG CCC 288

Gly Val Thr Thr Ser Gly Ser Ser Leu Thr Met Asn Gln Tyr Met Pro

85

90

95

AGC AGC TCT GGC GGC TAC AGC AGC GTC TCT CCT CGG CTG TAT CTC CTG 336

Ser Ser Ser Gly Gly Tyr Ser Ser Val Ser Pro Arg Leu Tyr Leu Leu

100

105

110

GAC TCT GAC GGT GAG TAC GTG ATG CTG AAG CTC AAC GGC CAG GAG CTG 384

Asp Ser Asp Gly Glu Tyr Val Met Leu Lys Leu Asn Gly Gln Glu Leu

115

120

125

AGC TTC GAC GTC GAC CTC TCT GCT CTG CCG TGT GGA GAG AAC GGC TCG 432

Ser Phe Asp Val Asp Leu Ser Ala Leu Pro Cys Gly Glu Asn Gly Ser

130

135

140

CTC TAC CTG TCT CAG ATG GAC GAG AAC GGG GGC GCC AAC CAG TAT AAC 480

Leu Tyr Leu Ser Gln Met Asp Glu Asn Gly Gly Ala Asn Gln Tyr Asn

145

150

155

160

ACG GCC GGT GCC AAC TAC GGG AGC GGC TAC TGC GAT GCT CAG TGC CCC 528

Thr Ala Gly Ala Asn Tyr Gly Ser Gly Tyr Cys Asp Ala Gln Cys Pro

165

170

175

- 64 -

| | |
|---|-----|
| GTC CAG ACA TGG AGG AAC GGC ACC CTC AAC ACT AGC CAC CAG GGC TTC | 576 |
| Val Gln Thr Trp Arg Asn Gly Thr Leu Asn Thr Ser His Gln Gly Phe | |
| 180 185 190 | |
| TGC TGC AAC GAG ATG GAT ATC CTG GAG GGC AAC TCG AGG GCG AAT GCC | 624 |
| Cys Cys Asn Glu Met Asp Ile Leu Glu Gly Asn Ser Arg Ala Asn Ala | |
| 195 200 205 | |
| TTG ACC CCT CAC TCT TGC ACG GCC ACG GCC TGC GAC TCT GCC GGT TGC | 672 |
| Leu Thr Pro His Ser Cys Thr Ala Thr Ala Cys Asp Ser Ala Gly Cys | |
| 210 215 220 | |
| GGC TTC AAC CCC TAT GGC AGC GGC TAC AAA AG GTGAGCCTGA | 714 |
| Gly Phe Asn Pro Tyr Gly Ser Gly Tyr Lys Ser | |
| 225 230 235 | |
| TGCCACTACT ACCCCTTTCC TGGCGCTCTC GCGGTTTTCC ATGCTGACAT GGTTTTCCAG | 774 |
| C TAC TAC GGC CCC GGA GAT ACC GTT GAC ACC TCC AAG ACC TTC ACC | 820 |
| Tyr Tyr Gly Pro Gly Asp Thr Val Asp Thr Ser Lys Thr Phe Thr | |
| 240 245 250 | |
| ATC ATC ACC CAG TTC AAC ACG GAC AAC GGC TCG CCC TCG GGC AAC CTT | 868 |
| Ile Ile Thr Gln Phe Asn Thr Asp Asn Gly Ser Pro Ser Gly Asn Leu | |
| 255 260 265 | |
| GTG AGC ATC ACC CGC AAG TAC CAG CAA AAC GGC GTC GAC ATC CCC AGC | 916 |
| Val Ser Ile Thr Arg Lys Tyr Gln Gln Asn Gly Val Asp Ile Pro Ser | |
| 270 275 280 | |

- 65 -

| | |
|---|------|
| GCC CAG CCC GGC GGC GAC ACC ATC TCG TCC TGC CCG TCC GCC TCA GCC | 964 |
| Ala Gln Pro Gly Gly Asp Thr Ile Ser Ser Cys Pro Ser Ala Ser Ala | |
| 285 290 295 | |
| TAC GGC GGC CTC GCC ACC ATG GGC AAG GCC CTG AGC AGC GGC ATG GTG | 1012 |
| Tyr Gly Gly Leu Ala Thr Met Gly Lys Ala Leu Ser Ser Gly Met Val | |
| 300 305 310 | |
| CTC GTG TTC AGC ATT TGG AAC GAC AAC AGC CAG TAC ATG AAC TGG CTC | 1060 |
| Leu Val Phe Ser Ile Trp Asn Asp Asn Ser Gln Tyr Met Asn Trp Leu | |
| 315 320 325 330 | |
| GAC AGC GGC AAC GCC GGC CCC TGC AGC AGC ACC GAG GGC AAC CCA TCC | 1108 |
| Asp Ser Gly Asn Ala Gly Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser | |
| 335 340 345 | |
| AAC ATC CTG GCC AAC AAC CCC AAC ACG CAC GTC GTC TTC TCC AAC ATC | 1156 |
| Asn Ile Leu Ala Asn Asn Pro Asn Thr His Val Val Phe Ser Asn Ile | |
| 350 355 360 | |
| CGC TGG GGA GAC ATT GGG TCT ACT ACG AAC TCG ACT GCG CCC CCG | 1201 |
| Arg Trp Gly Asp Ile Gly Ser Thr Thr Asn Ser Thr Ala Pro Pro | |
| 365 370 375 | |

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 377 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

- 66 -

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Gln Gln Pro Gly Thr Ser Thr Pro Glu Val His Pro Lys Leu Thr Thr
1 5 10 15

Tyr Lys Cys Thr Lys Ser Gly Gly Cys Val Ala Gln Asp Thr Ser Val
20 25 30

Val Leu Asp Trp Asn Tyr Arg Trp Met His Asp Ala Asn Tyr Asn Ser
35 40 45

Cys Thr Val Asn Gly Gly Val Asn Thr Thr Leu Cys Pro Asp Glu Ala
50 55 60

Thr Cys Gly Lys Asn Cys Phe Ile Glu Gly Val Asp Tyr Ala Ala Ser
65 70 75 80

Gly Val Thr Thr Ser Gly Ser Ser Leu Thr Met Asn Gln Tyr Met Pro
85 90 95

Ser Ser Ser Gly Gly Tyr Ser Ser Val Ser Pro Arg Leu Tyr Leu Leu
100 105 110

Asp Ser Asp Gly Glu Tyr Val Met Leu Lys Leu Asn Gly Gln Glu Leu
115 120 125

Ser Phe Asp Val Asp Leu Ser Ala Leu Pro Cys Gly Glu Asn Gly Ser
130 135 140

Leu Tyr Leu Ser Gln Met Asp Glu Asn Gly Gly Ala Asn Gln Tyr Asn
145 150 155 160

Thr Ala Gly Ala Asn Tyr Gly Ser Gly Tyr Cys Asp Ala Gln Cys Pro
165 170 175

Val Gln Thr Trp Arg Asn Gly Thr Leu Asn Thr Ser His Gln Gly Phe
180 185 190

Cys Cys Asn Glu Met Asp Ile Leu Glu Gly Asn Ser Arg Ala Asn Ala

- 67 -

| | | |
|---|-----|-----|
| 195 | 200 | 205 |
| Leu Thr Pro His Ser Cys Thr Ala Thr Ala Cys Asp Ser Ala Gly Cys | | |
| 210 | 215 | 220 |
| Gly Phe Asn Pro Tyr Gly Ser Gly Tyr Lys Ser Tyr Tyr Gly Pro Gly | | |
| 225 | 230 | 235 |
| Asp Thr Val Asp Thr Ser Lys Thr Phe Thr Ile Ile Thr Gln Phe Asn | | |
| | 245 | 250 |
| | | 255 |
| Thr Asp Asn Gly Ser Pro Ser Gly Asn Leu Val Ser Ile Thr Arg Lys | | |
| | 260 | 265 |
| | | 270 |
| Tyr Gln Gln Asn Gly Val Asp Ile Pro Ser Ala Gln Pro Gly Gly Asp | | |
| 275 | 280 | 285 |
| Thr Ile Ser Ser Cys Pro Ser Ala Ser Ala Tyr Gly Gly Leu Ala Thr | | |
| 290 | 295 | 300 |
| Met Gly Lys Ala Leu Ser Ser Gly Met Val Leu Val Phe Ser Ile Trp | | |
| 305 | 310 | 315 |
| | | 320 |
| Asn Asp Asn Ser Gln Tyr Met Asn Trp Leu Asp Ser Gly Asn Ala Gly | | |
| | 325 | 330 |
| | | 335 |
| Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser Asn Ile Leu Ala Asn Asn | | |
| | 340 | 345 |
| | | 350 |
| Pro Asn Thr His Val Val Phe Ser Asn Ile Arg Trp Gly Asp Ile Gly | | |
| 355 | 360 | 365 |
| Ser Thr Thr Asn Ser Thr Ala Pro Pro | | |
| 370 | 375 | |

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1158 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(1..56, 231..1158)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

| | |
|---|-----|
| GGG GTC CGA TTT GCC GGC GTT AAC ATC GCG GGT TTT GAC TTT GGC TGT | 48 |
| Gly Val Arg Phe Ala Gly Val Asn Ile Ala Gly Phe Asp Phe Gly Cys | |
| 1 5 10 15 | |
| ACC ACA GA GTGAGTACCC TTGTTTCCTG GTGTTGCTGG CTGTTGGGC | 96 |
| Thr Thr Asp | |
| GGGTATACAG CGAAGCGGAC GCAAGAACAC CGCCGGTCCG CCACCATCAA GATGTGGGTG | 156 |
| GTAAGCGGCG GTGTTTTGTA CAACTACCTG ACAGCTCACT CAGGAAATGA GAATTAATGG | 216 |
| AAGTCTTGTT ACAG T GGC ACT TGC GTT ACC TCG AAG GTT TAT CCT CCG | 264 |
| Gly Thr Cys Val Thr Ser Lys Val Tyr Pro Pro | |
| 20 25 30 | |
| TTG AAG AAC TTC ACC GGC TCA AAC AAC TAC CCC GAT GGC ATC GGC CAG | 312 |
| Leu Lys Asn Phe Thr Gly Ser Asn Asn Tyr Pro Asp Gly Ile Gly Gln | |
| 35 40 45 | |
| ATG CAG CAC TTC GTC AAC GAG GAC GGG ATG ACT ATT TTC CGC TTA CCT | 360 |
| Met Gln His Phe Val Asn Glu Asp Gly Met Thr Ile Phe Arg Leu Pro | |
| 50 55 60 | |
| GTC GGA TGG CAG TAC CTC GTC AAC AAC AAT TTG GGC GGC AAT CTT GAT | 408 |

- 69 -

Val Gly Trp Gln Tyr Leu Val Asn Asn Asn Leu Gly Gly Asn Leu Asp

65

70

75

TCC ACG AGC ATT TCC AAG TAT GAT CAG CTT GTT CAG GGG TGC CTG TCT 456

Ser Thr Ser Ile Ser Lys Tyr Asp Gln Leu Val Gln Gly Cys Leu Ser

80

85

90

CTG GGC GCA TAC TGC ATC GTC GAC ATC CAC AAT TAT GCT CGA TGG AAC 504

Leu Gly Ala Tyr Cys Ile Val Asp Ile His Asn Tyr Ala Arg Trp Asn

95

100

105

110

GGT GGG ATC ATT GGT CAG GGC GGC CCT ACT AAT GCT CAA TTC ACG AGC 552

Gly Gly Ile Ile Gly Gln Gly Gly Pro Thr Asn Ala Gln Phe Thr Ser

115

120

125

CTT TGG TCG CAG TTG GCA TCA AAG TAC GCA TCT CAG TCG AGG GTG TGG 600

Leu Trp Ser Gln Leu Ala Ser Lys Tyr Ala Ser Gln Ser Arg Val Trp

130

135

140

TTC GGC ATC ATG AAT GAG CCC CAC GAC GTG AAC ATC AAC ACC TGG GCT 648

Phe Gly Ile Met Asn Glu Pro His Asp Val Asn Ile Asn Thr Trp Ala

145

150

155

GCC ACG GTC CAA GAG GTT GTA ACC GCA ATC CGC AAC GCT GGT GCT ACG 696

Ala Thr Val Gln Glu Val Val Thr Ala Ile Arg Asn Ala Gly Ala Thr

160

165

170

TCG CAA TTC ATC TCT TTG CCT GGA AAT GAT TGG CAA TCT GCT GGG GCT 744

Ser Gln Phe Ile Ser Leu Pro Gly Asn Asp Trp Gln Ser Ala Gly Ala

175

180

185

190

- 70 -

| | |
|---|------|
| TTC ATA TCC GAT GGC AGT GCA GCC GCC CTG TCT CAA GTC ACG AAC CCG | 792 |
| Phe Ile Ser Asp Gly Ser Ala Ala Ala Leu Ser Gln Val Thr Asn Pro | |
| 195 200 205 | |
| GAT GGG TCA ACA ACG AAT CTG ATT TTT GAC GTG CAC AAA TAC TTG GAC | 840 |
| Asp Gly Ser Thr Thr Asn Leu Ile Phe Asp Val His Lys Tyr Leu Asp | |
| 210 215 220 | |
| TCA GAC AAC TCC GGT ACT CAC GCC GAA TGT ACT ACA AAT AAC ATT GAC | 888 |
| Ser Asp Asn Ser Gly Thr His Ala Glu Cys Thr Thr Asn Asn Ile Asp | |
| 225 230 235 | |
| GGC GCC TTT TCT CCG CTT GCC ACT TGG CTC CGA CAG AAC AAT CGC CAG | 936 |
| Gly Ala Phe Ser Pro Leu Ala Thr Trp Leu Arg Gln Asn Asn Arg Gln | |
| 240 245 250 | |
| GCT ATC CTG ACA GAA ACC GGT GGT GGC AAC GTT CAG TCC TGC ATA CAA | 984 |
| Ala Ile Leu Thr Glu Thr Gly Gly Gly Asn Val Gln Ser Cys Ile Gln | |
| 255 260 265 270 | |
| GAC ATG TGC CAG CAA ATC CAA TAT CTC AAC CAG AAC TCA GAT GTC TAT | 1032 |
| Asp Met Cys Gln Gln Ile Gln Tyr Leu Asn Gln Asn Ser Asp Val Tyr | |
| 275 280 285 | |
| CTT GGC TAT GTT GGT TGG GGT GCC GGA TCA TTT GAT AGC ACG TAT GTC | 1080 |
| Leu Gly Tyr Val Gly Trp Gly Ala Gly Ser Phe Asp Ser Thr Tyr Val | |
| 290 295 300 | |
| CTG ACG GAA ACA CCG ACT AGC AGT GGT AAC TCA TGG ACG GAC ACA TCC | 1128 |

- 71 -

Leu Thr Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp Thr Asp Thr Ser

305

310

315

TTG GTC AGC TCG TGT CTC GCA AGA AAG TA

1158

Leu Val Ser Ser Cys Leu Ala Arg Lys

320

325

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 327 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Gly Val Arg Phe Ala Gly Val Asn Ile Ala Gly Phe Asp Phe Gly Cys

1

5

10

15

Thr Thr Asp Gly Thr Cys Val Thr Ser Lys Val Tyr Pro Pro Leu Lys

20

25

30

Asn Phe Thr Gly Ser Asn Asn Tyr Pro Asp Gly Ile Gly Gln Met Gln

35

40

45

His Phe Val Asn Glu Asp Gly Met Thr Ile Phe Arg Leu Pro Val Gly

50

55

60

Trp Gln Tyr Leu Val Asn Asn Asn Leu Gly Gly Asn Leu Asp Ser Thr

65

70

75

80

- 72 -

Ser Ile Ser Lys Tyr Asp Gln Leu Val Gln Gly Cys Leu Ser Leu Gly

85

90

95

Ala Tyr Cys Ile Val Asp Ile His Asn Tyr Ala Arg Trp Asn Gly Gly

100

105

110

Ile Ile Gly Gln Gly Gly Pro Thr Asn Ala Gln Phe Thr Ser Leu Trp

115

120

125

Ser Gln Leu Ala Ser Lys Tyr Ala Ser Gln Ser Arg Val Trp Phe Gly

130

135

140

Ile Met Asn Glu Pro His Asp Val Asn Ile Asn Thr Trp Ala Ala Thr

145

150

155

160

Val Gln Glu Val Val Thr Ala Ile Arg Asn Ala Gly Ala Thr Ser Gln

165

170

175

Phe Ile Ser Leu Pro Gly Asn Asp Trp Gln Ser Ala Gly Ala Phe Ile

180

185

190

Ser Asp Gly Ser Ala Ala Ala Leu Ser Gln Val Thr Asn Pro Asp Gly

195

200

205

Ser Thr Thr Asn Leu Ile Phe Asp Val His Lys Tyr Leu Asp Ser Asp

210

215

220

Asn Ser Gly Thr His Ala Glu Cys Thr Thr Asn Asn Ile Asp Gly Ala

225

230

235

240

- 73 -

Phe Ser Pro Leu Ala Thr Trp Leu Arg Gln Asn Asn Arg Gln Ala Ile

245

250

255

Leu Thr Glu Thr Gly Gly Gly Asn Val Gln Ser Cys Ile Gln Asp Met

260

265

270

Cys Gln Gln Ile Gln Tyr Leu Asn Gln Asn Ser Asp Val Tyr Leu Gly

275

280

285

Tyr Val Gly Trp Gly Ala Gly Ser Phe Asp Ser Thr Tyr Val Leu Thr

290

295

300

Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp Thr Asp Thr Ser Leu Val

305

310

315

320

Ser Ser Cys Leu Ala Arg Lys

325

2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 81 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..81

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

- 74 -

CCC CCG CCT GCG TCC AGC ACG ACG TTT TCG ACT ACA CCG AGG AGC TCG 48
Pro Pro Pro Ala Ser Ser Thr Thr Phe Ser Thr Thr Pro Arg Ser Ser
1 5 10 15

ACG ACT TCG AGC AGC CCG AGC TGC ACG CAG ACT 81
Thr Thr Ser Ser Ser Pro Ser Cys Thr Gln Thr
20 25

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Pro Pro Pro Ala Ser Ser Thr Thr Phe Ser Thr Thr Pro Arg Ser Ser
1 5 10 15
Thr Thr Ser Ser Ser Pro Ser Cys Thr Gln Thr
20 25

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..102

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCG GGA GCC ACT ACT ATC ACC ACT TCG ACC CGG CCA CCA TCC GGT CCA 48
Pro Gly Ala Thr Thr Ile Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro
1 5 10 15

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| ACC | ACC | ACC | ACC | AGG | GCT | ACC | TCA | ACA | AGC | TCA | TCA | ACT | CCA | CCC | ACG | 96 |
| Thr | Thr | Thr | Thr | Arg | Ala | Thr | Ser | Thr | Ser | Ser | Ser | Thr | Pro | Pro | Thr | |
| 20 | | | | 25 | | | | 30 | | | | | | | | |

| | |
|---------|-----|
| AGC TCT | 102 |
| Ser Ser | |

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Pro Gly Ala Thr Thr Ile Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro

1 5 10 15

Thr Thr Thr Thr Arg Ala Thr Ser Thr Ser Ser Ser Thr Pro Pro Thr
20 25 30
Ser Ser

- 76 -

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 66 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..66

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATG GCG CCC TCA GTT ACA CTG CCG TTG ACC ACG GCC ATC CTG GCC ATT 48

Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala Ile Leu Ala Ile

1 5 10 15

GCC CGG CTC GTC GCC GCC 66

Ala Arg Leu Val Ala Ala

20

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala Ile Leu Ala Ile

1 5 10 15

- 77 -

Ala Arg Leu Val Ala Ala

20

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..63

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATG AAC AAG TCC GTG GCT CCA TTG CTG CTT GCA GCG TCC ATA CTA TAT 48

Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser Ile Leu Tyr

1 5 10 15

GGC GGC GCC GTC GCA 63

Gly Gly Ala Val Ala

20

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 78 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser Ile Leu Tyr

1

5

10

15

Gly Gly Ala Val Ala

20

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 777 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AAACCAGCTG TGACCAGTGG GCAACCTTCA CTGGCAACGG CTACACAGTC AGCAACAACC 60

TTTGGGGAGC ATCAGCCGGC TCTGGATTG GCTGCGTGAC GGCGGTATCG CTCAGCGGCG 120

GGGCCTCCTG GCACGCAGAC TGGCAGTGGT CCGGCGGCCA GAACAACGTC AAGTCGTACC 180

AGAACTCTCA GATTGCCATT CCCCAGAAGA GGACCGTCAA CAGCATCAGC AGCATGCCCCA 240

CCACTGCCAG CTGGAGCTAC AGCGGGAGCA ACATCCGCGC TAATGTTGCG TATGACTTGT 300

TCACCGCAGC CAACCCGAAT CATGTCACGT ACTCGGGAGA CTACGAACTC ATGATCTGGT 360

AAGCCATAAG AAGTGACCCT CCTTGATAGT TTCGACTAAC AACATGTCTT GAGGCTTGGC 420

- 79 -

AAATACGGCG ATATTGGGCC GATTGGGTCC TCACAGGGAA CAGTCAACGT CGGTGGCCAG 480

AGCTGGACGC TCTACTATGG CTACAACGGA GCCATGCAAG TCTATTCCTT TGTGGCCCAG 540

ACCAACACTA CCAACTACAG CGGAGATGTC AAGAACTTCT TCAATTATCT CCGAGACAAT 600

AAAGGATACA ACGCTGCAGG CCAATATGTT CTTAGTAAGT CACCCTCACT GTGACTGGGC 660

TGAGTTTGTT GCAACGTTTG CTAACAAAAC CTTCGTATAG GCTACCAATT TGGTACCGAG 720

CCCTTCACGG GCAGTGGAAC TCTGAACGTC GCATCCTGGA CCGCATCTAT CAACTAA 777

2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 218 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Gln Thr Ser Cys Asp Gln Trp Ala Thr Phe Thr Gly Asn Gly Tyr Thr
 1 5 10 15

Val Ser Asn Asn Leu Trp Gly Ala Ser Ala Gly Ser Gly Phe Gly Cys
 20 25 30

Val Thr Ala Val Ser Leu Ser Gly Gly Ala Ser Trp His Ala Asp Trp
 35 40 45

- 80 -

Gln Trp Ser Gly Gly Gln Asn Asn Val Lys Ser Tyr Gln Asn Ser Gln
50 55 60

Ile Ala Ile Pro Gln Lys Arg Thr Val Asn Ser Ile Ser Ser Met Pro
65 70 75 80

Thr Thr Ala Ser Trp Ser Tyr Ser Gly Ser Asn Ile Arg Ala Asn Val
85 90 95

Ala Tyr Asp Leu Phe Thr Ala Ala Asn Pro Asn His Val Thr Tyr Ser
100 105 110

Gly Asp Tyr Glu Leu Met Ile Trp Leu Gly Lys Tyr Gly Asp Ile Gly
115 120 125

Pro Ile Gly Ser Ser Gln Gly Thr Val Asn Val Gly Gly Gln Ser Trp
130 135 140

Thr Leu Tyr Tyr Gly Tyr Asn Gly Ala Met Gln Val Tyr Ser Phe Val
145 150 155 160

Ala Gln Thr Asn Thr Thr Asn Tyr Ser Gly Asp Val Lys Asn Phe Phe
165 170 175

Asn Tyr Leu Arg Asp Asn Lys Gly Tyr Asn Ala Ala Gly Gln Tyr Val
180 185 190

Leu Ser Tyr Gln Phe Gly Thr Glu Pro Phe Thr Gly Ser Gly Thr Leu
195 200 205

- 81 -

Asn Val Ala Ser Trp Thr Ala Ser Ile Asn

210

215

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATGAAGTTCC TTCAAGTCCT CCCTGCCCTC ATACCGGCCG CCCTGGCCC

49

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Met Lys Phe Leu Gln Val Leu Pro Ala Leu Ile Pro Ala Ala Leu Ala

1

5

10

15

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

- 82 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGCTCGTAGA GCGTTGACTT GCCTGTGGTC TGTCCAGACG GGGGACGATA GAATGCG

57

Claims:

1. The use of a composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase.
2. The use according to claim 1, wherein the composition is free of any cellobiohydrolase.
3. The use according to claim 1 or claim 2, wherein the one or more endoglucanases are obtainable from a fungal source.
4. The use according to any preceding claim, wherein the feed additive comprises at least one of EGI, EGII, EGIII, or a derivative of any thereof.
5. The use according to any preceding claim, wherein the endoglucanase(s) is/are obtainable from a genetically modified strain of the fungus *Trichoderma*.
6. The use according to claim 5, wherein the genetically modified strain is derived from *T. longibrachiatum*, *T. reesei* or *T. viride* whose genome has been modified so that it is enriched in its production of one or more endoglucanases and/or unable to produce one or more functionally active cellobiohydrolases.
7. The use according to claim 6, wherein the genome of the genetically modified strain is also unable to produce functionally active EGI and/or EGII.

8. The use according to any of claims 1-6, wherein the one or more endoglucanases are EGI which lacks the cellulose binding domain and/or EGII which lacks the cellulose binding domain.

9. An enzyme-based feed additive which comprises at least one of EGIII, EGI which lacks the cellulose binding domain and EGII which lacks the cellulose binding domain, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.

10. An enzyme-based feed additive comprising a cereal-based carrier, one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.

11. An enzyme-based feed additive according to claim 10, wherein the cereal-based carrier is one or more of milled wheat, maize, milled soya or a by-product of any of these materials.

12. An enzyme-based feed additive according to any of claims 9-11, wherein the additive further comprises one or more additional enzymes selected from a xylanase, a protease, an α -amylase, a glucoamylase, a lipase, a pectinase, a mannanase, an α -galactosidase, an α -arabinofuranosidase, an α -arabinofuranosidase and a phytase.

- 85 -

13. An enzyme-based feed additive according to claim 12, wherein the xylanase is the high pI xylanase and/or the low pI xylanase of *T. longibrachiatum*.

14. An enzyme-based feed additive according to claim 12 or claim 13, wherein the protease is a subtilisin or mutant thereof derived from the genus *Bacillus*.

15. A cereal-based animal feed comprising at least one cereal selected from barley, wheat, triticale, rye and maize, and an enzyme-based feed additive according to any of claims 9-14.

16. The use of a cereal-based feed according to claim 15, for feeding poultry.

1/11

TGTGTTGAAATCCAACCTTATAAAGACAACAACCGCAAACCTTTGTCTTGTG 50
CCATCAGATTGTTGCCAAGCACCGTCCCCCCCCCTATCTTAGTCCTTCT 100
TGTGTGCCAAAATGGCGCCCTCAGTTACACTGCCGTTGACCACGGCCAT 150
Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala Ile
CCTGGCCATTGCCCCGGCTCGTCGCCGCCAGCAACCGGGTACCAGCACCC 200
Leu Ala Ile Ala Arg Leu Val Ala Ala Gln Gln Pro Gly Thr Ser Thr
CCGAGGTCCATCCCAAGTTGACAACCTACAAGTGTACAAAGTCCGGGGGG 250
Pro Glu Val His Pro Lys Leu Thr Thr Tyr Lys Cys Thr Lys Ser Gly Gly
TGGTGGCCCAGGACACCTCGGTGGTCCTTGACTGGAACCTACCGCTGGAT 300
Cys Val Ala Gln Asp Thr Ser Val Val Leu Asp Trp Asn Tyr Arg Trp Met
GCACGACGCAAACCTACAACCTCGTGACCGTCAACGGCGGCGTCAACACCA 350
His Asp Ala Asn Tyr Asn Ser Cys Thr Val Asn Gly Gly Val Asn Thr
CGCTCTGCCCTGACGAGGCGACCTGTGGCAAGAACTGCTTCATCGAGGGC 400
Thr Leu Cys Pro Asp Glu Ala Thr Cys Gly Lys Asn Cys Phe Ile Glu Gly
GTCGACTACGCCGCTCGGGCGTCACGACCTCGGGCAGCAGCCTCACCAT 450
Val Asp Tyr Ala Ala Ser Gly Val Thr Thr Ser Gly Ser Ser Leu Thr Met
GAACCAGTACATGCCCAGCAGCTCTGGCGGCTACAGCAGCGTCTCTCCTC 500
Asn Gln Tyr Met Pro Ser Ser Ser Gly Gly Tyr Ser Ser Val Ser Pro
GGCTGTATCTCCTGGACTCTGACGGTGAGTACGTGATGCTGAAGCTCAAC 550
Arg Leu Tyr Leu Leu Asp Ser Asp Gly Glu Tyr Val Met Leu Lys Leu Asn
GGCCAGGAGCTGAGCTTCGACGTCGACCTCTCTGCTCTGCCGTGTGGAGA 600
Gly Gln Glu Leu Ser Phe Asp Val Asp Leu Ser Ala Leu Pro Cys Gly Glu
GAACGGCTCGCTCTACCTGTCTCAGATGGACGAGAACGGGGGCGCCAACC 650
Asn Gly Ser Leu Tyr Leu Ser Gln Met Asp Glu Asn Gly Gly Ala Asn
AGTATAACACGGCCGGTGCCAACTACGGGAGCGGCTACTGCGATGCTCAG 700
Gln Tyr Asn Thr Ala Gly Ala Asn Tyr Gly Ser Gly Tyr Cys Asp Ala Gln
TGCCCCGTCCAGACATGGAGGAACGGCACCTCAACACTAGCCACCAGGG 750
Cys Pro Val Gln Thr Trp Arg Asn Gly Thr Leu Asn Thr Ser His Gln Gly
CTTCTGCTGCAACGAGATGGATATCCTGGAGGGCAACTCGAGGGCGAATG 800
Phe Cys Cys Asn Glu Met Asp Ile Leu Glu Gly Asn Ser Arg Ala Asn

FIG. 1A

SUBSTITUTE SHEET (RULE 26)

2/11

CCTTGACCCCTCACTCTTGACGGCCACGGCCTGCGACTCTGCCGGTTGC 850
 Ala Leu Thr Pro His Ser Cys Thr Ala Thr Ala Cys Asp Ser Ala Gly Cys
 GGCTTCAACCCCTATGGCAGCGGCTACAAAAGGTGAGCCTGATGCCACTA 900
 Gly Phe Asn Pro Tyr Gly Ser Gly Tyr Lys Ser
 CTACCCCTTTCTGGCGCTCTCGCGGTTTTCCATGCTGACATGGTTTTCC 950
 AGCTACTACGGCCCCGGAGATACCGTTGACACCTCCAAGACCTTCACCAT 1000
 — Tyr Tyr Gly Pro Gly Asp Thr Val Asp Thr Ser Lys Thr Phe Thr Ile
 CATCACCCAGTTCAACACGGACAACGGCTCGCCCTCGGGCAACCTTGTGA 1050
 Ile Thr Gln Phe Asn Thr Asp Asn Gly Ser Pro Ser Gly Asn Leu Val
 GCATCACCCGCAAGTACCAGCAAAACGGCGTCGACATCCCCAGCGCCCAG 1100
 Ser Ile Thr Arg Lys Tyr Gln Gln Asn Gly Val Asp Ile Pro Ser Ala Gln
 CCGGGCGGCGACACCATCTCGTCCTGCCCCTCCGCCTCAGCCTACGGCGG 1150
 Pro Gly Gly Asp Thr Ile Ser Ser Cys Pro Ser Ala Ser Ala Tyr Gly Gly
 CCTCGCCACCATGGGCAAGGCCCTGAGCAGCGGCATGGTGCTCGTGTTC 1200
 Leu Ala Thr Met Gly Lys Ala Leu Ser Ser Gly Met Val Leu Val Phe
 GCATTTGGAACGACAACAGCCAGTACATGAAGTGGCTCGACAGCGGCAAC 1250
 Ser Ile Trp Asn Asp Asn Ser Gln Tyr Met Asn Trp Leu Asp Ser Gly Asn
 GCCGGCCCCCTGCAGCAGCACCGAGGGCAACCCATCCAACATCCTGGCCAA 1300
 Ala Gly Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser Asn Ile Leu Ala Asn
 CAACCCCAACACGCACGTCGTCTTCTCCAACATCCGCTGGGGAGACATTG 1350
 Asn Pro Asn Thr His Val Val Phe Ser Asn Ile Arg Trp Gly Asp Ile
 GGTCTACTACGAAGTCTGACTGCGCCCCCGCCCCGCCTGCGTCCAGCAGG 1400
 Gly Ser Thr Thr Asn Ser Thr Ala Pro Pro Pro Pro Pro Ala Ser Ser Thr
 ACGTTTTCTGACTACACCGAGGAGCTCGACGACTTCGAGCAGCCCGAGCTG 1450
 Thr Phe Ser Thr Thr Pro Arg Ser Ser Thr Thr Ser Ser Ser Pro Ser Cys
 CACGCAGACTCACTGGGGGCAAGTGCGGTGGCATTGGGTACAGCGGGTGCA 1500
 Thr Gln Thr His Trp Gly Gln Cys Gly Gly Ile Gly Tyr Ser Gly Cys
 AGACGTGCACGTCGGGCACTACGTGCCAGTATAGCAACGACTGTTTCGTAT 1550
 Lys Thr Cys Thr Ser Gly Thr Thr Cys Gln Tyr Ser Asn Asp —

FIG. 1B

3/11

CCCCATGCCTGACGGGAGTGATTTTGAGATGCTAACCGCTAAAATACAGA 1600
CTACTCGCAATGCCTTTAGAGCGTTGACTTGCCTCTGGTCTGTCCAGACG 1650
Tyr Ser Gln Cys Leu •
GGGGCACGATAGAATGCGGGCACGCAGGGA 1680

FIG. 1 C**FIG. 1****FIG. 1 A****FIG. 1 B****FIG. 1 C**

4/11

TGCCATTTCTGACCTGGATAGGTTTTCTATGGTCATTCTATAAGAGAC 50
ACGCTCTTTTCGTCGGCCCGTAGATATCAGATTGGTATTAGTCGCACAGA 100
CGAAGGTGAGTTGATCCTCCAACATGAGTTCTATGAGCCCCCCCCCTTGCC 150
CCCCCCCGTTTACCTTGACCTGCAATGAGAATCCCACCTTTTACAAGAGC 200
ATCAAGAAGTATTAATGGCGCTGAATAGCCTCTGCTCGATAATATCTCCC 250
CGTCATCGACAATGAACAAGTCCGTGGCTCCATTGCTGCTTGCAGCGTCC 300
Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser
ATACTATATGGCGGGCGCCGTCGCACAGCAGACTGTCTGGGGCCAGTGTGG 350
Ile Leu Tyr Gly Gly Ala Val Ala Gln Gln Thr Val Trp Gly Gln Cys Gly
AGGTATTGGTTGGAGCGGACCTACGAATTGTGCTCCTGGCTCAGCTTGTT 400
Gly Ile Gly Trp Ser Gly Pro Thr Asn Cys Ala Pro Gly Ser Ala Cys
CGACCCTCAATCCTTATTATGCGCAATGTATTCCGGGAGCCACTACTATC 450
Ser Thr Leu Asn Pro Tyr Tyr Ala Gln Cys Ile Pro Gly Ala Thr Thr Ile
ACCACTTCGACCCGGCCACCATCCGGTCCAACCACCACCACCAGGGCTAC 500
Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro Thr Thr Thr Thr Arg Ala Thr
CTCAACAAGCTCATCAACTCCACCCACGAGCTCTGGGGTCCGATTTGCCG 550
Ser Thr Ser Ser Ser Thr Pro Pro Thr Ser Ser Gly Val Arg Phe Ala
GCGTTAACATCGCGGGTTTTGACTTTGGCTGTACCACAGAGTGAGTACCC 600
Gly Val Asn Ile Ala Gly Phe Asp Phe Gly Cys Thr Thr Asp
TTGTTTCTCGGTGTTGCTGGCTGGTTGGGCGGGTATACAGCGAAGCGGAC 650
GCAAGAACACCGCCGGTCCGCCACCATCAAGATGTGGGTGGTAAGCGGCG 700
GTGTTTTGTACAACTACCTGACAGCTCACTCAGGAAATGAGAATTAATGG 750
AAGTCTTGTTACAGTGGCACTTGCGTTACCTCGAAGGTTTATCCTCCGTT 800
Gly Thr Cys Val Thr Ser Lys Val Tyr Pro Pro Leu
GAAGAACTTCACCGGCTCAAACAACTACCCCGATGGCATCGGCCAGATGC 850
Lys Asn Phe Thr Gly Ser Asn Asn Tyr Pro Asp Gly Ile Gly Gln Met

FIG. 2 A

5/11

AGCACTTCGTCAACGAGGACGGGATGACTATTTTCCGCTTACCTGTCGGA 900
Gln His Phe Val Asn Glu Asp Gly Met Thr Ile Phe Arg Leu Pro Val Gly
TGGCAGTACCTCGTCAACAACAATTGGGCGGCAATCTTGATTCCACGAG 950
Trp Gln Tyr Leu Val Asn Asn Asn Leu Gly Gly Asn Leu Asp Ser Thr Ser
CATTTCCAAGTATGATCAGCTTGTTTCAGGGGTGCCTGTCTCTGGGCGCAT 1000
Ile Ser Lys Tyr Asp Gln Leu Val Gln Gly Cys Leu Ser Leu Gly Ala
ACTGCATCGTCGACATCCACAATTATGCTCGATGGAACGGTGGGATCATT 1050
Tyr Cys Ile Val Asp Ile His Asn Tyr Ala Arg Trp Asn Gly Gly Ile Ile
GGTCAGGGCGGCCCTACTAATGCTCAATTCACGAGCCTTTGGTCGCAGTT 1100
Gly Gln Gly Gly Pro Thr Asn Ala Gln Phe Thr Ser Leu Trp Ser Gln Leu
GGCATCAAAGTACGCATCTCAGTCGAGGGTGTGGTTCGGCATCATGAATG 1150
Ala Ser Lys Tyr Ala Ser Gln Ser Arg Val Trp Phe Gly Ile Met Asn
AGCCCCACGACGTGAACATCAACACCTGGGCTGCCACGGTCCAAGAGGTT 1200
Glu Pro His Asp Val Asn Ile Asn Thr Trp Ala Ala Thr Val Gln Glu Val
GTAACCGCAATCCGCAACGCTGGTGCTACGTCGCAATTCATCTCTTTGCC 1250
Val Thr Ala Ile Arg Asn Ala Gly Ala Thr Ser Gln Phe Ile Ser Leu Pro
TGGAATGATTGGCAATCTGCTGGGGCTTTTCATATCCGATGGCAGTGCAG 1300
Gly Asn Asp Trp Gln Ser Ala Gly Ala Phe Ile Ser Asp Gly Ser Ala
CCGCCCTGTCTCAAGTCACGAACCCGGATGGGTCAACAACGAATCTGATT 1350
Ala Ala Leu Ser Gln Val Thr Asn Pro Asp Gly Ser Thr Thr Asn Leu Ile
TTTGACGTGCACAAATACTTGGACTCAGACAACCTCCGGTACTCACGCCGA 1400
Phe Asp Val His Lys Tyr Leu Asp Ser Asp Asn Ser Gly Thr His Ala Glu
ATGTACTACAAATAACATTGACGGCGCCTTTTCTCCGCTTGCCACTTGGC 1450
Cys Thr Thr Asn Asn Ile Asp Gly Ala Phe Ser Pro Leu Ala Thr Trp
TCCGACAGAACAATCGCCAGGCTATCCTGACAGAAACCGGTGGTGGCAAC 1500
Leu Arg Gln Asn Asn Arg Gln Ala Ile Leu Thr Glu Thr Gly Gly Gly Asn
GTTTCAGTCCTGCATACAAGACATGTGCCAGCAAATCCAATATCTCAACCA 1550
Val Gln Ser Cys Ile Gln Asp Met Cys Gln Gln Ile Gln Tyr Leu Asn Gln
GAACTCAGATGTCTATCTTGGCTATGTTGGTTGGGGTGCCGGATCATTTG 1600
Asn Ser Asp Val Tyr Leu Gly Tyr Val Gly Trp Gly Ala Gly Ser Phe

FIG. 2 B

6/11

ATAGCACGTATGTCCTGACGGAAACACCGACTAGCAGTGGTAACTCATGG 1650
Asp Ser Thr Tyr Val Leu Thr Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp
ACGGACACATCCTTGGTCAGCTCGTGTCTCGCAAGAAAGTAGCACTCTGA 1700
Thr Asp Thr Ser Leu Val Ser Ser Cys Leu Ala Arg Lys •
GCTGAATGCAGAAGCCTCGCCAACGTTTGTATCTCGCTATCAAACATAGT 1750
AGCTACTCTATGAGGCTGTCTGTTCTCGATTTTCAGCTTTATATAGTTTCA 1800
TCAAACAGTACATATTCCCTCTGTGGCCACGCAAAAAAAAAAAAAAAAAAAAA 1849

FIG. 2 C**FIG. 2****FIG. 2 A****FIG. 2 B****FIG. 2 C**

7/11

GGGTGGTCTGGATGAAACGTCTTGGCCAAATCGTGATCGATTGATACTCG 50
CATCTATAAGATGGCACAGATCGACTCTTGATTACAGACATCCGTCAGC 100
CCTCAAGCCGTTTGC AAGTCCACAAACACAAGCACAAGCATAGCGTCGCA 150
ATGAAGTTCCTTCAAGTCCTCCCTGCCCTCATACCGGCCGCCCTGGCCCA 200
Met Lys Phe Leu Gln Val Leu Pro Ala Leu Ile Pro Ala Ala Leu Ala Gln
AACCAGCTGTGACCAGTGGGCAACCTTCACTGGCAACGGCTACACAGTCA 250
Thr Ser Cys Asp Gln Trp Ala Thr Phe Thr Gly Asn Gly Tyr Thr Val
GCAACAACCTTTGGGGAGCATCAGCCGGCTCTGGATTTGGCTGCGTGACG 300
Ser Asn Asn Leu Trp Gly Ala Ser Ala Gly Ser Gly Phe Gly Cys Val Thr
GCGGTATCGCTCAGCGGCGGGGCCTCCTGGCACGCAGACTGGCAGTGGTC 350
Ala Val Ser Leu Ser Gly Gly Ala Ser Trp His Ala Asp Trp Gln Trp Ser
CGGCGGCCAGAACAACGTCAAGTCGTACCAGAACTCTCAGATTGCCATTC 400
Gly Gly Gln Asn Asn Val Lys Ser Tyr Gln Asn Ser Gln Ile Ala Ile
CCCAGAAGAGGACCGTCAACAGCATCAGCAGCATGCCACCACTGCCAGC 450
Pro Gln Lys Arg Thr Val Asn Ser Ile Ser Ser Met Pro Thr Thr Ala Ser
TGGAGCTACAGCGGGAGCAACATCCGCGCTAATGTTGCGTATGACTTGTT 500
Trp Ser Tyr Ser Gly Ser Asn Ile Arg Ala Asn Val Ala Tyr Asp Leu Phe
CACCGCAGCCAACCCGAATCATGTCACGTACTCGGGAGACTACGAACTCA 550
Thr Ala Ala Asn Pro Asn His Val Thr Tyr Ser Gly Asp Tyr Glu Leu
TGATCTGGTAAGCCATAAGAAGTGACCCTCCTTGATAGTTTCGACTAACA 600
Met Ile Trp


FIG. 3 A

8/11

ACATGTCTTGAGGCTTGGCAAATACGGCGATATTGGGCCGATTGGGTCCT 650
Leu Gly Lys Tyr Gly Asp Ile Gly Pro Ile Gly Ser
CACAGGGAACAGTCAACGTCGGTGGCCAGAGCTGGACGCTCTACTATGGC 700
Ser Gln Gly Thr Val Asn Val Gly Gly Gln Ser Trp Thr Leu Tyr Tyr Gly
TACAACGGAGCCATGCAAGTCTATTCCCTTTGTGGCCCAGACCAACACTAC 750
Tyr Asn Gly Ala Met Gln Val Tyr Ser Phe Val Ala Gln Thr Asn Thr Thr
CAACTACAGCGGAGATGTCAAGAACTTCTTCAATTATCTCCGAGACAATA 800
Asn Tyr Ser Gly Asp Val Lys Asn Phe Phe Asn Tyr Leu Arg Asp Asn
AAGGATACAACGCTGCAGGCCAATATGTTCTTAGTAAGTCACCCTCACTG 850
Lys Gly Tyr Asn Ala Ala Gly Gln Tyr Val Leu Ser
TGA CTGGGCTGAGTTTGTTGCAACGTTTGCTAACAAAACCTTCGTATAGG 900
CTACCAATTTGGTACCGAGCCCTTCACGGGCAGTGGA ACTCTGAACGTCG 950
Tyr Gln Phe Gly Thr Glu Pro Phe Thr Gly Ser Gly Thr Leu Asn Val
CATCCTGGACCGCATCTATCAACTAAAACCTGGAAACGTGAGATGTGGTG 1000
Ala Ser Trp Thr Ala Ser Ile Asn
GGCATACGTTATTGAGCGAGGGAAAAAAGCATTGGATCCATTGAAGATG 1050


FIG. 3B**FIG. 3****FIG. 3A****FIG. 3B**

9/11



- Digest with BsmI and EcoRI
- Isolate 300bp BsmI/EcoRI Fragment
- Digest pUC218 with SstI and EcoRI
- Ligate pUC218 SstI/EcoRI and BamI/EcoRI fragment with the following synthetic oligonucleotides (SEQ. ID NO:37)

CGTAGAGCGTTGACTTGCCCTGTGGTCTGTCCAGACGGGGGACGATAGAATGCG
 TCGAGCATCTCGCAACTGAACGGACACCAGACAGGTCTGCCCCCTGCTATCTTAC
 SstI BsmI




- Digest pEG1T with HindIII and BsmI and Isolate vector fragment
- Digest pUC218::EG1 with HindIII and SstI and Isolate 2.3 kb EG1 fragment
- Ligate pEG1T HindIII/BsmI and 2.3 Kb HindIII/SstI with the following synthetic oligonucleotides


CGTAGAGCGTTGACTTGCCCTGTGGTCTGTCCAGACGGGGGACGATAGAATGCG
 TCGAGCATCTCGCAACTGAACGGACACCAGACAGGTCTGCCCCCTGCTATCTTAC
 SstI BsmI

FIG. 4 A

10/11



- Digest p219M with **EcoRI** and **HindIII**
- Isolate 1.6Kb **EcoRI/HindIII** *pyr4* gene fragment
- Digest pUC218 with **EcoRI** **SstI** and dephosphorylate the ends with calf alkaline phosphatase
- Isolate the **HindIII/EcoRI** EG1 fragment from pEG1Δ3'
- Ligate together pUC18 **EcoRI**, **EcoRI/HindIII** *pyr4* gene fragment and **HindIII/EcoRI** EG1 fragment

**FIG. 4 A****FIG. 4 B****FIG. 4****FIG. 4 B**

11/11

Endoglucanases

Viscosity Reducing Activity




Fig 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 94/04212

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A23K1/165

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A23K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | WO,A,91 18090 (OY ALKO AB) 28 November 1991 see page 35, line 15 - line 20 see examples 1-3 see claims 1-3,7-11,13 | 1-9 |
| Y | --- | 10-16 |
| Y | WO,A,91 04673 (NOVO NORDISK A/S) 18 April 1991 cited in the application see page 3, line 21 - page 4, line 7 see examples 1-3,6 see claims 1-5 --- -/-- | 10-16 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

5 April 1995

Date of mailing of the international search report

24. 04. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Dekeirel, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 94/04212

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | WO,A,93 20714 (SSV-DEVELOPMENT OY) 28 October 1993 see page 1, line 5 - line 16 see page 5, line 13 - line 20 see page 6, line 26 - page 7, line 19 see page 8, line 2 - page 9, line 8 see page 10, line 5 - line 21 see page 26, line 17 - line 20 see examples 1,4 see claims 1-39 ---- | 1-16 |
| X | WO,A,90 09436 (CARLSBERG A/S) 23 August 1990 see page 5, line 28 - page 6, line 6 see claims 66,67 ---- | 1,9,15, 16 |
| X | JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE., vol.63, no.1, 1993, BARKING GB pages 107 - 108 M. R. BEDFORD 'Feed enzymes in barley-based diets' see page 107, column 1, last paragraph - page 108, column 2, paragraph 2 ---- | 1,9,15, 16 |
| A | WO,A,92 06184 (GENENCOR INTERNATIONAL, INC.) 16 April 1992 see page 28, line 11 - line 17 ---- | 1-7 |
| A | WO,A,92 06209 (GENENCOR INTERNATIONAL INC.) 16 April 1992 cited in the application see the whole document ----- | 1-8 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern al Application No

PCT/EP 94/04212

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|--|
| WO-A-9118090 | 28-11-91 | US-A- 5298405 AU-A- 7869891 EP-A- 0532533 | 29-03-94 10-12-91 24-03-93 |
| WO-A-9104673 | 18-04-91 | DE-D- 69007115 DE-T- 69007115 EP-A- 0494916 JP-T- 5500807 | 07-04-94 09-06-94 22-07-92 18-02-93 |
| WO-A-9320714 | 28-10-93 | AU-B- 3954093 CA-A- 2133748 EP-A- 0634899 FI-A- 944724 NO-A- 943782 | 18-11-93 28-10-93 25-01-95 07-10-94 09-12-94 |
| WO-A-9009436 | 23-08-90 | AU-B- 638695 AU-A- 5101390 CA-A- 2050468 EP-A- 0458846 JP-T- 5504462 | 08-07-93 05-09-90 17-08-90 04-12-91 15-07-93 |
| WO-A-9206184 | 16-04-92 | US-A- 5290474 CA-A- 2093423 EP-A- 0586375 US-A- 5328841 | 01-03-94 01-12-92 16-03-94 12-07-94 |
| WO-A-9206209 | 16-04-92 | CA-A- 2093421 CA-A- 2093424 CA-A- 2093428 EP-A- 0551386 EP-A- 0551394 EP-A- 0552276 EP-A- 0553280 FI-A- 931490 FI-A- 931491 FI-A- 931495 JP-T- 6502223 JP-T- 6502205 JP-T- 6511379 JP-T- 6502226 | 06-04-92 06-04-92 06-04-92 21-07-93 21-07-93 28-07-93 04-08-93 31-05-93 25-05-93 27-05-93 10-03-94 10-03-94 22-12-94 10-03-94 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 94/04212

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO-A-9206209 | | WO-A- 9206210 | 16-04-92 |
| | | WO-A- 9206221 | 16-04-92 |
| | | WO-A- 9206183 | 16-04-92 |
| | | US-A- 5246853 | 21-09-93 |
| | | US-A- 5290474 | 01-03-94 |
| | | US-A- 5328841 | 12-07-94 |
| ----- | | | |